The Nimble Stage 1 Study Validates Diagnostic Circulating Biomarkers for Nonalcoholic Steatohepatitis

The Nimble Stage 1 Study Validates Diagnostic Circulating Biomarkers for Nonalcoholic Steatohepatitis | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Article The Nimble Stage 1 Study Validates Diagnostic Circulating Biomarkers for Nonalcoholic Steatohepatitis Arun Sanyal, Sudha Shankar, Katherine Yates, James Bolognese, and 15 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-2492725/v1 This work is licensed under a CC BY 4.0 License Status: Published Journal Publication published 07 Sep, 2023 Read the published version in Nature Medicine → Version 1 posted You are reading this latest preprint version Abstract Background There are no approved noninvasive tests (NIT) for the diagnosis of nonalcoholic steatohepatitis (NASH) and its histological phenotypes. Methods The FNIH-NIMBLE consortium tested 5 serum-based NIT panels for the following intended uses: NIS4: At-risk NASH, a composite of NASH with NAFLD activity score (NAS) ≥ 4 and fibrosis stage ≥ 2, OWLiver: NASH and NAS ≥ 4, enhanced liver fibrosis (ELF), PROC3 and Fibrometer VCTE: fibrosis stages ≥ 2, ≥ 3 or 4. Aliquots from a single blood sample obtained within 90 days of histological confirmation of NAFLD were tested. The prespecified performance metric tested for was a diagnostic AUROC greater than 0.7 and superiority to ALT for diagnosis of NASH or NAS ≥ 4 and to FIB-4 for fibrosis. Results A total of 1073 adults including NASH (n = 848), at-risk NASH (n = 539) and fibrosis stages 0–4 (n = 222, 114, 262, 277 and 198 respectively) were studied. The AUROC of NIS4 for at-risk NASH was 0.81 and superior to ALT and FIB4 (p < 0.001 for both). OWliver diagnosed NASH with sensitivity and specificity of 77.3% and 66.8% respectively. The AUROCs (95% CI) of ELF, PROC3 and Fibrometer VCTE respectively for fibrosis were as follows: ≥ stage 2 fibrosis [0.82 (0.8–0.85), 0.8 (0.77–0.83), and 0.84 (0.79–0.88)], ≥ stage 3 [0.83 (0.8–0.86), 0.76 (0.73–0.79), 0.85 (0.81–0.9), stage 4 [0.85 (0.81–0.89), 0.81 (0.77–0.85), 0.89 (0.84–0.95)]. ELF and Fibrometer VCTE were significantly superior to FIB-4 for all fibrosis endpoints (p < 0.01 for all). Conclusions These data support the further development of NIS4, ELF and Fibrometer VCTE for their intended uses. Health sciences/Biomarkers/Diagnostic markers Health sciences/Biomarkers Nonalcoholic fatty liver disease (NAFLD) Nonalcoholic steatohepatitis (NASH) NAFLD activity score (NAS) Fibrosis stage cirrhosis steatohepatitis fibrosis biomarkers diagnostic panel context of use validation Figures Figure 1 Figure 2 Introduction Nonalcoholic fatty liver disease (NAFLD) is a leading cause of liver-related morbidity and mortality 1 . The presence of nonalcoholic steatohepatitis (NASH) an active form of NAFLD and fibrosis stage of 2 or higher is linked to increased risk of liver outcomes and death 2 – 4 . Identification of such individuals and targeting them for therapeutic intervention is a cornerstone of clinical assessment and inclusion in clinical trials 5 . Histological evaluation of liver biopsy sections is the reference standard for assessment of NASH but requires an invasive liver biopsy with its associated risks which has limited its widespread use 6 – 8 . This has spurred much work to establish non-invasive tests (NITs) to diagnose NASH and fibrosis, yet none have met the evidence burden needed for regulatory approval. Validation of such NITs to regulatory standards remains a major unmet need for the field. The N on- I nvasive B ioMarkers of M eta B olic L iver Diseas E (NIMBLE) consortium was established by the Foundation-NIH (FNIH) to generate evidence to support advanced regulatory qualification of one or more NITs for the evaluation of nonalcoholic fatty liver disease (NAFLD) 9 . The current study represents a collaborative effort between the NIMBLE consortium and the National Institute of Diabetes and Digestive and Kidney Diseases-NASH Clinical Research Network (CRN). The objective was to perform a cross-sectional study to rigorously define the sensitivity and specificity of five serum-based NIT panels for the diagnosis of one or more of the following: NASH, high histological NAFLD activity and subpopulations with clinically relevant stages of fibrosis including cirrhosis. The panels were pre-selected on the basis of their analytic robustness, available literature and potential for scale-up for widespread use. The final results of this study are presented below. Materials And Methods Serum samples collected from adult participants with NAFLD in a non-interventional registry (database 1 and 2 (DB1 and DB2) and baseline samples from clinical trials (PIVENS and FLINT) across 12 NIDDK NASH CRN clinical sites ( supplemental Table 1 ) were analyzed. Participants were enrolled across these studies from 2004-2017 and provided informed consent at enrollment; the use of de-identified samples and meta-data was considered exempt from additional consenting requirements. The investigators have analyzed the data and take responsibility for the contents of this manuscript. The studies were done in accordance to STARD guidance and reported using the TRIPOD statement 10,11 . Context of Use In individuals with NAFLD or with risk-factors for NAFLD, to serve as a diagnostic enrichment tool for the identification of various histological phenotypes of NAFLD, intended for selection for participation in NAFLD/NASH clinical trials and/or drug treatment. Those who were overweight or obese, or had other features of metabolic syndrome were considered to be at risk for NAFLD 12 . The presence of specific phenotypes to be diagnosed included: At risk NASH: (NASH + NAFLD activity score (NAS) ≥ 4 + fibrosis stage 2 or higher) 9 Nonalcoholic steatohepatitis (borderline or definite) A NAS ≥ 4 Clinically significant fibrosis (fibrosis stage ≥ 2) Advanced fibrosis (stage 3 or 4) Cirrhosis (stage 4) Study Design A: Study population The study population was curated from the CRN patient base to ensure sufficient number of individuals with and without the histological phenotypes of interest and a balanced distribution of fibrosis stages to avoid spectrum bias. The current analysis included aliquots from a serum-sample obtained within 90-180 days of an evaluable liver biopsy demonstrating NAFLD. For Fibrometer VCTE (vibration-controlled transient elastography), a liver stiffness measurement was required within 180 days of the biopsy. Exclusion criteria included pregnancy at the time of sample collection or biopsy, co-morbid liver diseases, use of drugs known to cause steatosis, non-availability of minimum required serum, bariatric surgery within 3 years prior to biopsy, prior liver transplant and known primary or secondary malignancy of the liver. B: Biomarker panels tested and their intended context of use Serum biomarker panels selected by the NIMBLE circulating workstream were reviewed and approved by the project team, NASH CRN ancillary study and steering committees. These included: NIS4 13 : mir34a, Hemoglobin A1c, α2-macroglobulin, YKL-40 OWliver 14 : triglyceride species with variable number of saturated fatty acids ELF test 15 : type III procollagen peptide, hyaluronic acid and TIMP-1 PROC3 16 : procollagen-3 fragment reflective of fibrogenesis Fibrometer VCTE 17 : LSM, age, gender, α2-macroglobulin, INR, platelet count, AST, GGT The intended use of NIS4 was to diagnose at-risk NASH and its components whereas the OWliver panels intended use was to diagnose the presence of NASH ( supplemental Table 2 ). The intended uses of the ELF test, PROC3 and Fibrometer VCTE were to diagnose clinically significant fibrosis (≥ stage 2 fibrosis), advanced fibrosis (≥ stage 3 fibrosis) or cirrhosis (stage 4 fibrosis). C: Study Approach The study plan was summarized in a letter of intent approved by the US federal government Food and Drug Administration 9,18 . De-identified, bar-coded frozen aliquots of the same serum sample from each participant without any prior freeze-thaw were released to the individual laboratories. These laboratories generated panel scores which were provided to the independent statistical team (Cytel) who deposited these in the CRN data warehouse. The CRN then released the meta-data linked to the bar codes to Cytel who implemented the prespecified statistical analysis plan without involvement of individual vendors whose panels were tested. The NIMBLE circulating workstream and statistical team then jointly reviewed the results and interpreted the data. D: Histological Examination: The pathology committee of the NASH CRN performed the histological assessment, masked to clinical and laboratory data, using an established and validated protocol 19,20 . The key measures included the presence of steatohepatitis and individual severity grades for steatosis (0-3), lobular inflammation (0-2), hepatocellular ballooning (0-2) and fibrosis stage (0-4). The NAS was computed from the scores for steatosis, ballooning and inflammation while “at risk” NASH was computed from the presence of its components 9,20 . Statistical Plan There were two pre-specified performance metrics which formed the basis for hypothesis-testing. First, that the area under receiver operating curve (AUROC) for each panel would be 0.7 or higher for its intended use with 95% confidence limits that would not intersect 0.5. Next, the biomarker performance would be superior to commonly used blood-based laboratory aids for their intended use. The AUROC of each panel was therefore compared to that of ALT for diagnosis of NASH or NAS≥ 4 and FIB-4, a commonly used laboratory aid based on age, AST, ALT and platelet counts, for diagnosis of fibrosis severity 21,22 . The sensitivity and specificity were computed at the Youden cut-point. The sensitivity was further estimated keeping specificity fixed at 90% and conversely specificity was measured keeping the sensitivity fixed at 90%. Finally, the positive and negative predictive values were computed at various prevalence of specific NAFLD phenotypes. Missing data were assumed missing at random from the statistical analysis, as they resulted from sample handling and laboratory issues independent of the relationship between biomarkers and histology; complete case-analysis was done. The sample size was estimated to detect a difference of at least 0.05 between the AUROC of FIB-4 or ALT and the relevant biomarker panel with a power of at least 80% with a one-sided p value of 0.025. It was assumed that the AUROC for FIB-4 would be 0.8 for fibrosis. Additionally, due to potential correlation between FIB-4 or ALT versus the biomarker panels, adjustments were made assuming the correlation coefficients ranging from 0.5-0.8. Based on these a total number of participants needed with NASH and fibrosis stage 2 or 3 versus 0 or 1 was 400 each. For analysis of cirrhosis, 180 individuals with cirrhosis were needed. Results The NASH CRN cohort had 4094 participants (Figure 1) . A total of 2479 individuals were excluded because of age, lack of samples or evaluable liver biopsies. Of the remaining individuals, consecutive patients for each stage of disease were selected to ensure that that enough patients were available to meet sample size estimates and to have a relatively balanced-distributed spectrum of fibrosis severity (stages 0-4, n= 222, 114, 262, 277 and 198 respectively). A total of 1073 individuals meeting eligibility criteria were thus included for this analysis with 90% of individuals having a serum sample within 90 days of the liver biopsy (Table 1) . The mean age of the cohort was 54 years and was preponderantly female and white. NAFL was present in 225 individuals while 835 had NASH and 13 an indeterminate NAFLD phenotype. Those without fibrosis were younger, had mainly had NAFL and lower NAS compared to those with fibrosis stage 2 or higher. The study population for Fibrometer VCTE was a smaller subset of the larger population (n= 396) for this analysis due to lack of availability of a VCTE examination within 6 months of the liver biopsy in many individuals. The baseline features of this subset were similar to the larger cohort ( supplemental Table 3 ). At-risk NASH NIS4 was the only panel with an intended use to diagnose underlying composite phenotype of “at risk” NASH (n=539) as defined above. The sensitivity and specificity were 78.1% and 73.6% respectively with an AUROC of 0.815 at the optimal cut-point (Table 2) . The AUROC was superior (p< 0.001 for both) to both ALT (AUROC 0.726) and FIB-4 (AUROC 0.704). NASH Diagnosis NIS4 and the OWLiver tests had an intended use to diagnose NASH ( supplemental Table 2 ). NIS4 (Youden cut-point 0.539) had an AUROC of 0.83 (95% CI 0.8-0.86) and was superior to ALT (AUROC 0.67) for this intended use (Table 2, Figure 2) . The sensitivity and specificity were 77.7% and 76.2% respectively at this cut-point. NIS4 had a specificity of 47.7% and sensitivity of 54.4% when sensitivity and specificity were constrained at 90% respectively ( supplemental table 4 ) and both were significantly superior to ALT (p<0.001 for both). The OWLiver provided the results in categorical format which did not permit generation of an AUROC; it diagnosed NASH with a sensitivity of 77.3%. and specificity of 66.8%. High NAFLD Activity Score (NAS ≥ 4) The AUROC (0.815, 95% CI 0.786-0.844) for NIS4 was significantly superior to ALT (AUROC 0.726, sensitivity 71.1%, specificity 64.1%) the comparator for panels intended to diagnose high activity (p<0.001). The specificity and sensitivity of NIS4 were 57.8% and 46.2% when sensitivity and specificity were locked at 90% respectively and both were significantly superior to ALT (p< 0.001 for both). Clinically significant fibrosis (Fibrosis stage ≥ 2): NIS4, ELF, PROC3 and Fibrometer VCTE had an intended use to identify clinically significant fibrosis in those with NAFLD. The AUROCs of NIS4, ELF, PROC3 and Fibrometer VCTE were 0.874, 0.828, 0.8 and 0.841 respectively. Their respective sensitivity and specificity at their Youden index are provided in Table 2. FIB-4 had an AUROC of 0.798 very close to the expected AUROC of 0.8 22 . NIS4 (p< 0.001), ELF (p< 0.01) and Fibrometer VCTE (p< 0.001) were all superior to FIB4. Similar data were obtained when the performance of these panels with sensitivity and specificity constrained at 90% were evaluated ( supplemental Table 4 ). Advanced fibrosis (Stages ≥ 3): The operational definition of advanced fibrosis included those with stage 3 or 4. The AUROCs of the panels tested for the diagnosis of advanced fibrosis were as follows: FIB-4 (0.789), ELF (0.835, p<0.001 vs FIB4), PROC3 (0.809, p=n.s. vs FIB-4), Fibrometer VCTE (0.841, p< 0.001 vs FIB4). A secondary analysis of NIS-4 for advanced fibrosis provided an AUROC of 0.78, p=n.s. vs FIB4). The sensitivity (ELF 50.3% and Fibrometer VCTE 54.2%) and specificity (ELF 55.3% and Fibrometer VCTE 59.6%) with specificity and sensitivity fixed at 90% respectively were both statistically superior to FIB-4 ( supplemental Table 4 ). Cirrhosis (stage 4) The AUROCs for the diagnosis of cirrhosis were 0.81 for FIB-4, 0.855 for ELF (p< 0.001 vs FIB-4) and 0.897 for Fibrometer VCTE (p=0.002 vs FIB-4). The sensitivity of ELF and Fibrometer VCTE at the Youden index were 82.1% and 94.2% while the specificities were 73.3% and 70.4% respectively. Their performance at 90% sensitivity (specificity: ELF 60.5%, Fibrometer VCTE 72.5%) and 90% specificity (Sensitivity: ELF 49%, Fibrometer VCTE: 66.7%) were also statistically superior to FIB-4 ( Supplemental Table 4 ). Discussion The regulatory path for approval of a diagnostic test requires rigorously established sensitivity and specificity in a study cohort that is both powered and balanced with respect to the presence or absence of the condition being studied. The current study establishes this first step and is the foundation for the use of specific cut-points in relevant populations in the next stage towards regulatory approval of these diagnostic enrichment tools for NASH 18 . The study has several methodological strengths. The time from biopsy to blood draw was short and all analyses including the comparators were made on the same blood sample. Further, all samples were drawn, aliquoted, stored and analyzed without multiple freeze-thaw using prespecified protocols. Histology was read independently using a rigorous pre-specified protocol by the pathology committee of the NASH CRN masked to clinical and laboratory data. The distribution of fibrosis stages in the cohort avoided spectrum bias. Finally, for each of the phenotypes studied, the sample size included enough number of individuals with and without the phenotype assuring power both for sensitivity and specificity. The practical application of these data has to be considered in the context of how the tests are used. In primary care where the prevalence of advanced fibrosis is 1%, positive tests are likely to be false positives and even with excellent sensitivity and specificity the PPV will be low 23 . Using these tests to identify patients for clinical trials in such settings are likely to have many false positives resulting in high screen fail rates. The NPV for FIB4 as well as all of the biomarker panels (ranged from 98-99.7% when the population prevalence of advanced fibrosis was 1% ( supplemental Table 5 ). These tests can therefore be applied for exclusion of this phenotype for both clinical management and for screening for trials of at-risk NASH in a primary care setting. The prevalence of at-risk NASH or its subsets NASH with advanced fibrosis or cirrhosis in hepatology clinic settings are higher and range from 10–40% 2,12,24 . It is encouraging to note that the high NPV in settings with low prevalence was maintained at these ranges while the positive predictive values approached 80% at the 40% prevalence when the Youden cut point was used ( supplemental Table 5 ). In clinical trial settings, these data should allow exclusion of those without these phenotypes while limiting overdiagnosis compared to a primary care setting. Additional enhancement of certainty for ruling in disease by using the cut point for 90% specificity will however be associated with a loss of sensitivity and attendant misclassification. Further improvement is likely to require an algorithmic approach using multiple panels or use of imaging-based tests for greater precision in identification of this population. Recently, MR-elastography with FIB4 or AST has been shown to identify those with NASH and advanced fibrosis or at-risk NASH respectively and may provide such tools 25 – 27 . The current data can’t however be directly compared to these due to methodological differences. For those with advanced fibrosis or cirrhosis, a mistaken diagnosis of absence of these phenotypes may cause patients to be followed without surveillance for hepatocellular cancer or varices. The overall high NPVs suggest that the risks are in general low. Conversely, overdiagnosis due to the modest PPVs may result in futile additional testing including liver biopsies with its attendant risks. ELF and Fibrometer VCTE can identify 82–94% of true positive cases of cirrhosis but also may over-diagnose some patients to have cirrhosis in clinics with high prevalence of cirrhosis (Table 5). The risks of overdiagnosis has to be considered in the context of the risks of missing advanced fibrosis or cirrhosis altogether in specific populations both in clinical practice and for consideration for inclusion in trials. This study also has some limitations. The NASH CRN is based at tertiary care centers generating ascertainment bias. The study population is predominantly white and the data are not generalizable to other races. Despite these limitations, the current study provides a rigorous evidence base to establish the sensitivity and specificity of these biomarker panels serves as a critical step in the ultimate regulatory approval of some of these panels as diagnostic enrichment tools in clinical practice and to determine eligibility for inclusion in clinical trials for NASH. References Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology (Baltimore, Md 2018;67(1):123–133. (Review Research Support, Non-U.S. Gov't) (In eng). DOI: 10.1002/hep.29466 . Kleiner DE, Brunt EM, Wilson LA, et al. Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease. JAMA network open 2019;2(10):e1912565. (In eng). DOI: 10.1001/jamanetworkopen.2019.12565 . Sanyal AJ, Van Natta ML, Clark J, et al. Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease. The New England journal of medicine 2021;385(17):1559–1569. DOI: 10.1056/NEJMoa2029349 . Dulai PS, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. Hepatology (Baltimore, Md 2017;65(5):1557–1565. (Meta-Analysis Review) (In eng). DOI: 10.1002/hep.29085 . FDA. Noncirrhotic Nonalcoholic Steatohepatitis With Liver Fibrosis: Developing Drugs for Treatment Guidance for Industry. US Food and Drug Administration; 2018. Rinella ME, Lominadze Z, Loomba R, et al. Practice patterns in NAFLD and NASH: real life differs from published guidelines. Therapeutic advances in gastroenterology 2016;9(1):4–12. (In eng). DOI: 10.1177/1756283X15611581 . Sanyal AJ. Past, present and future perspectives in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2019;16(6):377–386. (Research Support, N.I.H., Extramural Review) (In eng). DOI: 10.1038/s41575-019-0144-8 . Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD, American Association for the Study of Liver D. Liver biopsy. Hepatology (Baltimore, Md 2009;49(3):1017–44. (Practice Guideline) (In eng). DOI: 10.1002/hep.22742 . Sanyal AJ, Shankar SS, Calle RA, et al. Non-Invasive Biomarkers of Nonalcoholic Steatohepatitis: the FNIH NIMBLE project. Nature medicine 2022. DOI: 10.1038/s41591-021-01652-8 . Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD). Annals of internal medicine 2015;162(10):735–6. (Comment Letter) (In eng). DOI: 10.7326/L15-5093-2 . Bossuyt PM, Reitsma JB, Bruns DE, et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Annals of internal medicine 2003;138(1):W1-12. (In eng) ( http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve &db=PubMed&dopt=Citation&list_uids=12513067). Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology (Baltimore, Md 2018;67(1):328–357. (Practice Guideline Research Support, Non-U.S. Gov't Review) (In eng). DOI: 10.1002/hep.29367 . Harrison SA, Ratziu V, Boursier J, et al. A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study. The lancet Gastroenterology & hepatology 2020 (In eng). DOI: 10.1016/S2468-1253(20)30252-1 . Mayo R, Crespo J, Martinez-Arranz I, et al. Metabolomic-based noninvasive serum test to diagnose nonalcoholic steatohepatitis: Results from discovery and validation cohorts. Hepatology communications 2018;2(7):807–820. (In eng). DOI: 10.1002/hep4.1188 . Guha IN, Parkes J, Roderick P, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology (Baltimore, Md 2008;47(2):455–60. (In eng) ( http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve &db=PubMed&dopt=Citation&list_uids=18038452). Luo Y, Oseini A, Gagnon R, et al. An Evaluation of the Collagen Fragments Related to Fibrogenesis and Fibrolysis in Nonalcoholic Steatohepatitis. Scientific reports 2018;8(1):12414. (Research Support, N.I.H., Extramural) (In eng). DOI: 10.1038/s41598-018-30457-y . Cales P, Boursier J, Oberti F, et al. FibroMeters: a family of blood tests for liver fibrosis. Gastroenterologie clinique et biologique 2008;32(6 Suppl 1):40–51. (In eng) ( http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve &db=PubMed&dopt=Citation&list_uids=18973845). DDTBMQ000084. Circulating Biomarkers for Diagnosis of Nonalcoholic steatohepatitis (NASH). 2020. Kleiner DE, Brunt EM. Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research. Seminars in liver disease 2012;32(1):3–13. (Research Support, N.I.H., Intramural Review) (In Eng). DOI: 10.1055/s-0032-1306421 . Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology (Baltimore, Md 2005;41(6):1313–21. (Multicenter Study Research Support, N.I.H., Extramural Research Support, U.S. Gov't, P.H.S. Validation Studies) (In eng). DOI: 10.1002/hep.20701 . Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology (Baltimore, Md 2006;43(6):1317-25. (Comparative Study Research Support, N.I.H., Extramural) (In eng). DOI: 10.1002/hep.21178 . Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009;7(10):1104-12. (Comparative Study Evaluation Studies Research Support, N.I.H., Extramural) (In eng). DOI: 10.1016/j.cgh.2009.05.033 . Huber Y, Schulz A, Schmidtmann I, et al. Prevalence and Risk Factors of Advanced Liver Fibrosis in a Population-Based Study in Germany. Hepatology communications 2022;6(6):1457–1466. DOI: 10.1002/hep4.1899 . Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116(6):1413–9. (In eng) ( http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve &db=PubMed&dopt=Citation&list_uids=10348825). Kim BK, Tamaki N, Imajo K, et al. Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD. Journal of hepatology 2022. DOI: 10.1016/j.jhep.2022.07.020 . Jung J, Loomba RR, Imajo K, et al. MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis. Gut 2021;70(10):1946–1953. DOI: 10.1136/gutjnl-2020-322976 . Ajmera V, Kim BK, Yang K, et al. Liver Stiffness on Magnetic Resonance Elastography and the MEFIB Index and Liver-Related Outcomes in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Individual Participants. Gastroenterology 2022. DOI: 10.1053/j.gastro.2022.06.073 . Tables Table 1: Demographic, Clinical and Laboratory Data from the Study Cohort Stage 0 Stage 1 Stage 2 Stage 3 Stage 4 N = 222 N = 114 N = 262 N = 277 N = 198 Age (years) 47.8 (12.2) 48.1 (13.8) 51.7 (11.5) 54.4 (11.2) 56.2 (9.8) Gender (males) [n (%)] 99 (44.6%) 52 (45.6%) 102 (38.9%) 91 (32.9%) 60 (30.3%) White [n (%)] 158 (71.2%) 68 (59.6%) 199 (76.2%) 217 (78.9%) 169 (86.2%) African American [n (%)] 4 (1.8%) 5 (4.4%) 8 (3.1%) 8 (2.9%) 3 (1.5%) Hispanic [n (%)] 34 (15.3%) 20 (17.5%) 28 (10.7%) 24 (8.7%) 16 (8.2%) Other [n (%)] 26 (11.7%) 21 (18.4%) 26 (10.0%) 26 (9.5%) 8 (4.1%) BMI (kg/m 2 ) 32.8 (6.6) 33.3 (6.1) 34.5 (6.3) 36.1 (6.6) 36.4 (7.3) Waist circ (cm) 104.7 (14.7) 107.3 (13.9) 110.8 (14.2) 114.3 (14.8) 113.7 (15.1) Type 2 diabetes [n (%)] 45 (20.3%) 41 (36.0%) 113 (43.1%) 162 (58.5%) 129 (65.2%) Hypertension [n (%)] 94 (42.3%) 65 (57.0%) 164 (62.6%) 191 (69.0%) 132 (66.7%) AST (IU/L) 27.8 (13.3) 31.9 (17.7) 50.3 (29.3) 58.3 (39.8) 51.9 (28.9) ALT (IU/L) 38.5 (25.4) 45.0 (34.6) 65.5 (43.1) 68.1 (47.8) 49.1 (34.5) ALP (IU/L) 86.6 (30.5) 80.6 (28.2) 87.0 (28.0) 93.0 (33.2) 114.5 (53.2) Total Bilirubin (mg/dL) 0.5 (0.3) 0.6 (0.5) 0.5 (0.3) 0.5 (0.4) 0.8 (0.8) INR 1.0 (0.1) 1.0 (0.2) 1.0 (0.1) 1.1 (0.1) 2.8 (4.3) Albumin (g/dL) 4.6 (0.3) 4.6 (0.3) 4.6 (0.3) 4.5 (0.3) 4.3 (0.4) Hemoglobin (g/dL) 14.4 (1.4) 14.3 (1.5) 14.2 (1.5) 13.9 (1.5) 13.6 (1.6) WBC (10 3 /µL) 7.0 (2.2) 7.1 (2.0) 7.3 (2.0) 7.6 (6.0) 6.5 (3.3) Platelet (cells/mL) 250.3 (62.7) 243.5 (82.9) 237.8 (60.5) 218.7 (66.2) 165.9 (64.1) Fasting glucose (mg/dL) 101.3 (33.8) 106.7 (42.0) 114.6 (42.2) 116.6 (34.8) 126.2 (51.7) Fasting insulin (µU/mL) 17.8 (14.2) 25.5 (32.4) 26.8 (29.1) 30.9 (27.6) 35.5 (35.4) Total cholesterol (mg/dL) 193.7 (43.1) 181.2 (43.3) 189.7 (48.5) 183.3 (42.3) 174.2 (40.4) LDL-C (mg/dL) 117.5 (36.5) 105.9 (36.6) 112.0 (39.2) 106.1 (38.1) 100.7 (35.3) HDL-C (mg/dL) 45.1 (10.9) 44.4 (13.5) 42.9 (11.9) 42.8 (11.9) 45.2 (13.2) Triglycerides (mg/dL) 169.8 (108.0) 168.1 (108.5) 203.1 (275.0) 186.3 (114.9) 141.5 (66.2) Statin Use [n (%)] 63 (28.4%) 46 (40.4%) 91 (34.7%) 113 (40.8%) 84 (42.4%) Time from biopsy to study entry (days) 55.16(24.32) 60.44(26.93) 53.60(25.24) 53.18(24.15) 79.31(39.22) NAFL [n (%)] 195 (87.8%) 23 (20.2%) 0 (0.0%) 0 (0.0%) 7 (3.5%) NASH [n (%)] 27 (12.2%) 91 (79.8%) 262 (100%) 277 (100%) 178 (89.9%) Steatosis grade 1.3 (0.5) 1.2 (0.4) 2.0 (0.8) 1.8 (0.9) 1.3 (0.9) Ballooning grade 0.1 (0.3) 0.3 (0.5) 1.2 (0.7) 1.5 (0.7) 1.5 (0.7) Lobular Inflammation 1.0 (0.3) 1.1 (0.3) 1.7 (0.7) 1.8 (0.7) 1.5 (0.7) Portal inflammation 0.8 (0.6) 0.9 (0.5) 1.2 (0.5) 1.4 (0.5) 1.7 (0.5) NAS 2.5 (0.6) 2.5 (0.6) 4.8 (1.5) 5.2 (1.6) 4.2 (1.6) All statistics presented are means (standard deviations), unless otherwise specified. *Time between the liver biopsy and study enrollment for 109 (10%) of the cohort was between 92-183 days. Table 2: Sensitivity and Specificity of individual panels for their intended use Sensitivity(%) Specificity (%) Youden AUROC Significance index (95% CI) (vs ALT or FIB4) NASH Diagnosis ALT 63.2 64.8 0.28 0.678[0.639,0.717] NIS4 77.7 76.2 0.539 0.832[0.801,0.864] <0.001 OWL 77.3 66.8 Categorical Data AUROC can’t be computed NAS ≥ 4 ALT 71.1 64.1 0.352 0.726[0.694,0.759] NIS4 78.1 73.6 0.517 0.815[0.786,0.844] <0.001 At risk NASH ALT 71.1 64.1 0.352 0.726[0.694. 0.759] FIB4 76.4 58.4 0.349 0.704[0.671, 0.737] NIS4 78.1 73.6 0.517 0.815[0.786.0.844] <0.001 Fibrosis stage ≥ 2 FIB4 65.6 80.6 0.462 0.798[0.768,0.828] ELF test 71.8 81.5 0.533 0.828[0.08,0.857] 0.013 NIS4 82.3 79.9 0.622 0.874[0.848,0.899] <0.001 PROC3 69.8 81 0.507 0.809[0.779,0.839] 0.279 Fibrometer VCTE 66.7 86.4 0.53 0.841[0.796,0.886] <0.001 Fibrosis stage ≥ 3 FIB4 70.3 72.4 0.427 0.789[0.758,0.819] ELF 80.8 70.2 0.509 0.835[0.807,0.863] <0.001 NIS4 72.9 74.8 0.476 0.788[0.757,0.820] 0.615 PROC3 71.4 71.4 0.428 0.764[0.732,0.795] 0.947 Fibrometer VCTE 76.2 81.3 0.575 0.858[0.814,0.902] <0.001 Fibrosis stage 4 FIB4 84.7 62.9 0.476 0.810[0.770,0.850] ELF 82.1 73.3 0.555 0.855[0.818,0.892] <0.001 NIS4 78.1 61.4 0.395 0.725[0.681,0.760] 1 PROC3 66.2 68.5 0.346 0.728[0.685,0.770] 1 Fibrometer VCTE 94.2 70.4 0.646 0.897[0.843,0.951] 0.002 *for NASH diagnosis, NAS ≥ 4, significance is computed from comparison to AUROC for ALT **for “at risk” NASH, the significance values are against AUROCS for both ALT and for FIB4 *** for fibrosis cutoffs, significance is computed from comparison to AUROC for FIB4 Declarations Conflicts of Interest: Dr. Arun Sanyal: Dr. Sanyal has stock options in Genfit, Akarna, Tiziana, Indalo, Durect Inversago and Galmed. He has served as a consultant to Astra Zeneca, Nitto Denko, Conatus, Nimbus, Salix, Tobira, Takeda, Jannsen, Gilead, Terns, Birdrock, Merck, Valeant, Boehringer-Ingelheim, Bristol Myers Squibb, Lilly, Hemoshear, Zafgen, Novartis, Novo Nordisk, Pfizer, Exhalenz and Genfit. He has been an unpaid consultant to Intercept, Echosens, Immuron, Galectin, Fractyl, Target-Pharma, Syntlogic, Affimune, Chemomab, Zydus, Nordic Bioscience, Albireo, Prosciento, Surrozen. His institution has received grant support from Gilead, Salix, Tobira, Bristol Myers, Shire, Intercept, Merck, Astra Zeneca, Malinckrodt, Cumberland and Novartis. He receives royalties from Elsevier and UptoDate. He recused himself from the analysis and interpretation of NIS4. Sudha Shankar: Dr. Shankar is an employee of Astra Zeneca. Katherine Yates: Ms. Yates has no conflicts to report. James Bolognese: Mr. Bolognese is a paid consultant for Cytel, Inc. Erica Daly: Dr. Daly is an employee of Cytel, Inc. Clayton Dehn: Mr. Dehn is a volunteer consultant for NIMBLE (P-value, LLC) Brent Neuschwander-Tetri: Consultant or advisor for Akero, Alimentiv, Allergan, Allysta, Alnylam, Amgen, Arrowhead, Axcella, Boehringer Ingelheim, BMS, Coherus, Cymabay, Durect, Enanta, Fortress, Genfit, Gilead, Glympse, GSK, Hepeon, High Tide, HistoIndex, Innovo, Intercept, Ionis, LG Chem, Lipocine, Madrigal, Medimmune, Merck, Mirum, NGM, NovoNordisk, Novus Therapeutics, pH-Pharma, Sagimet, Target RWE, Theratechnologies, 89Bio; Institutional research grants: Allergan, BMS, Celgene, Cirius, Enanta, Genfit, Gilead, HighTide, Intercept, Madrigal, NGM; Stock options in HepGene. Kris Kowdley: Dr. Kowdley has received Grant/research/clinical trial support from Corcept, CymaBay, Genfit, Gilead, GSK, Hanmi, Intercept, Madrigal, Mirum, Novo Nordisk, NGM, Pfizer, Pliant, Terns, Viking, 89bio. He has served as Consultant or on advisory boards from CymaBay, Enanta, Genfit, Gilead, HighTide, Inipharm, Intercept, Madrigal, Mirum, NGM, Pfizer, 89bio. He sevres on the Speaker’s bureau for AbbVie, Gilead, Intercept and has Stock options from Inipharm. Raj Vuppalanchi: Dr. Vuppalanchi receives institutional research grant support from Zydus Therapeutics, Galectin Therapeutics, Gilead Sciences, Novo Nordisk, Eli Lilly, and also discloses consulting for LabCorp, GSK, Medpace, GW Pharma, Daichi Sankyo, and Echosens. Cynthia Behling: Dr. Behling has provided consulting or participated in seminars/preceptorships for Alimentev, Pfizer and Novo Nordisk. Dr. Cynthia Behling’s institution (Pacific Rim Pathology Laboratory/Analytic Pathology Medical Group) currently receives support for biopsy related work through nonexclusive laboratory services and/or consulting agreements with: Akero Therapeutics Inc, Covance, E study site, Genesis Imaging Service, ICON, Medical Research Group, Inc., Southern California Research Center. James Tonascia: Dr. Tonascia has no conflicts to report. Anthony Samir: Dr. Samir has provided consulting for General Electric and Gerson Lehman Group, is a member of the Advisory or Scientific Board for General Electric, Rhino Healthtech, Ochre Bio, and Foundation for the National Institutes of Health; has research support from Canon, Echosens, General Electric, Philips, Siemens, Supersonic Imagine/Hologic and has research funding from Analogic Corporation, Department of Defense, Fujifilm Healthcare, Foundation for the National Institutes of Health, and General Electric; and has equity in Avira Inc., Autonomus LLC, Evidence Based Psychology LLC, Klea LLC, Katharos Labs LLC, Quantix Bio LLC, and Sonoluminous LLC. Claude Sirlin: Dr. Sirlin reports research grants from ACR, Bayer, Foundation of NIH, GE, Gilead, Pfizer, Philips, Siemens; lab service agreements with Enanta, Gilead, ICON, Intercept, Nusirt, Shire, Synageva, Takeda; institutional consulting for BMS, Exact Sciences, IBM-Watson, Pfizer; Personal consulting for Blade, Boehringer, Epigenomics; and Guerbet; receipt of royalties and/or honoraria from Medscape and Wolters Kluwer; ownership of stock options in Livivos; unpaid advisory board position in Quantix Bio. Dr. Sirlin has been approved by his university to serve as Chief Medical Officer for Livivos (to be an unsalaried position with stock options). Sarah Sherlock: Dr. Sherlock is an employee of Pfizer, Inc. and has shares/stock options. Kathryn Fowler Dr. Fowler Dr. Fowler reports institutional research support from Bayer, Foundation of NIH, GE, Gilead, Pfizer, Philips, Siemens; lab service agreements with Enanta, Gilead, ICON, Intercept, Nusirt, Shire, Synageva, Takeda; personal consulting-Bayer, GE, Epigenomics. Unpaid advisory board Quantix Bio. Helen Heymann Ms. Heymann has no conflicts to report. Tania Kamphaus: Dr. Kamphaus has no conflicts to report. Dr. Loomba: Dr. Loomba serves as a consultant or advisory board member for 89bio, Alnylam, Arrowhead Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Bristol-Myer Squibb, Cirius, CohBar, DiCerna, Galmed, Gilead, Glympse bio, Intercept, Ionis, Metacrine, NGM Biopharmaceuticals, Novo Nordisk, Pfizer, Sagimet and Viking Therapeutics. In addition, his institution has received grant support from Allergan, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, Galmed Pharmaceuticals, Genfit, Gilead, Intercept, Inventiva, Janssen, Madrigal Pharmaceuticals, NGM Biopharmaceuticals, Novartis, Pfizer, pH Pharma, and Siemens. He is also co-founder of Liponexus, Inc. Roberto Calle: Dr. Calle is an employee of Regeneron Pharmaceuticals, Inc. and owns stock in both Regeneron and Pfizer. Source of funding The authors thank the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) investigators and the Ancillary Studies Committee for providing clinical samples and relevant data from the Nonalcoholic Fatty Liver Disease (NAFLD) Database, Nonalcoholic Fatty Liver Disease (NAFLD) Adult Database 2, PIVENS trial, and FLINT trial. This work was partially funded by the NIDDK (grants U01DK061731, U01DK061730, U24DK061730) and the National Center for Advancing Translational Sciences (NCATS) grant UL1TR002649. The PIVENS trial was conducted by the NASH CRN and supported in part by Takeda Pharmaceuticals North America through a Cooperative Research and Development Agreement with the NIDDK. The vitamin E and matching placebo for the PIVENS trial were provided by Pharmavite through a Clinical Trial Agreement with the NIH. The FLINT trial was conducted by the NASH CRN and supported in part by a Collaborative Research and Development Agreement (CRADA) between NIDDK and Intercept Pharmaceuticals. FNIH-NIMBLE project- Foundation for the National Institutes of Health (FNIH) -Biomarkers Consortium, Non-Invasive Biomarkers for Metabolic Liver Disease (NIMBLE) Project The FNIH creates and manages alliances with public and private institutions in support of the mission of the NIH, the world’s premier medical research agency. The FNIH works with its partners to accelerate biomedical research and strategies for addressing diseases and health concerns in the United States and across the globe. The FNIH organizes and administers research projects; supports education and training of new researchers; organizes educational events and symposia; and administers a series of funds supporting a wide range of health issues. Established by Congress in 1990, the FNIH is a not-for-profit 501(c)(3) charitable organization. The NIMBLE Project is a comprehensive multi-year pre-competitive, public-private partnership conducted under the auspices of the FNIH- Biomarkers Consortium. The Biomarkers Consortium embraces government, industry, patient advocacy groups, and not-for-profit organizations each of which has a stake in the identification, development, and the seeking of regulatory approval for biomarkers. The NIMBLE project is sponsored by the FNIH and is a public–private partnership supported by multiple entities including AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Echosens, GE Healthcare, Genentech, Gilead Sciences, Intercept Pharmaceuticals, Novo Nordisk, Pfizer Inc, Regeneron Pharmaceuticals and Takeda Development Center Americas. We acknowledge support from the Global Liver Institute, USA, and the US FDA. The FNIH NIMBLE study was conducted by the NASH CRN and FNIH Investigators and supported by NIDDK. The biospecimens from the NASH CRN reported here were supplied by the NIDDK Central Repository. This manuscript was not prepared in collaboration with the NIDDK Central Repository and does not necessarily reflect the opinions or views of the NIDDK Central Repository. Key collaborators who provide in-kind support to NIMBLE include AMRA Medical, Canon Medical Systems USA, Echosens, GENFIT, GE Healthcare, Nordic Bioscience, OWL Metabolomics, Philips Ultrasound, P-Value, Hologic SuperSonic Imagine, Siemens Healthineers and Siemens Medical Solutions USA. The laboratories that performed the chemical analyses and reported raw data to the NIMBLE data coordinating center were as follows: NIS4 (Genfit and Labcorp), Lille, France ELF test: Siemens Healthineers, California, USA PROC3: Nordic Biosciences, Copenhagen, Denmark Owliver: One Way Lipidomics (OWL), Bilbao, Spain Fibrometer VCTE: Echosens, Paris, France Data Availability Statement: Included in supplemental materials Abbreviations Nonalcoholic fatty liver disease (NAFLD), Nonalcoholic steatohepatitis (NASH), NAFLD activity score (NAS), Body Mass Index (BMI), Type 2 Diabetes Mellitus (T2DM), Additional Declarations Yes there is potential Competing Interest. these are provided in the manuscript Supplementary Files SupplementalTables.docx Cite Share Download PDF Status: Published Journal Publication published 07 Sep, 2023 Read the published version in Nature Medicine → Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-2492725","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Article","associatedPublications":[],"authors":[{"id":169162494,"identity":"9744f425-1fca-4ed9-9e11-f2500e988544","order_by":0,"name":"Arun Sanyal","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAABC0lEQVRIiWNgGAWjYHAD5sYHQDIByGhgJlILY7MBRAtjYzOxWtokiNLCP/uM2QOGP3Z5BscPtlXz1BzO42c/2P64gMEmX94BuxaJcznmBoxtycUGZxLbbvMcO1ws2ZPY2DyDIc1y4wEc1pzhMZNgbGBO3HAgse3mzIbDIEZjMw/DYQPDBuw65EFaGP7UJ244/7CtEKRl//mH+LUYgLWwAQ2/kdjG8BFkiwTUFnkc7jI8w1Ymkdh2PHHmjYfNEh+OpSfOuPGwcTaPQZqBAQ4tcmeYt0l8+FOd2Hc++eCHhBrrxP7+5AOfeSpsDORxOAwMEoBY4QCqg4HoABalyADTTLy2jIJRMApGwUgCAPm2Y0KycksBAAAAAElFTkSuQmCC","orcid":"https://orcid.org/0000-0001-8682-5748","institution":"Virginia Commonwealth University School of Medicine","correspondingAuthor":true,"submittingAuthor":false,"prefix":"","firstName":"Arun","middleName":"","lastName":"Sanyal","suffix":""},{"id":169162495,"identity":"06074fa4-9c51-4181-b7d4-7f0b3495ce33","order_by":1,"name":"Sudha Shankar","email":"","orcid":"","institution":"Astrazeneca","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Sudha","middleName":"","lastName":"Shankar","suffix":""},{"id":169162496,"identity":"0a6e1590-bcee-4d27-a528-3a642ea80d0f","order_by":2,"name":"Katherine Yates","email":"","orcid":"","institution":"Bloomberg School of Public Health, Johns Hopkins University","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Katherine","middleName":"","lastName":"Yates","suffix":""},{"id":169162497,"identity":"36eb5f0b-ed3e-4cd0-9fa1-dcfb38e7b32b","order_by":3,"name":"James Bolognese","email":"","orcid":"","institution":"Cytel, Inc.","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"James","middleName":"","lastName":"Bolognese","suffix":""},{"id":169162498,"identity":"dd2bd11d-bf7d-41a7-8e67-76ac688689a3","order_by":4,"name":"Erica Daly","email":"","orcid":"","institution":"Cytel, Inc.","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Erica","middleName":"","lastName":"Daly","suffix":""},{"id":169162499,"identity":"42170440-cfe0-4d87-94b3-8be5a8ff8d70","order_by":5,"name":"Clayton Dehn","email":"","orcid":"","institution":"P-Value","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Clayton","middleName":"","lastName":"Dehn","suffix":""},{"id":169162500,"identity":"0d07027f-3431-4cdd-b982-fd3f46f71b9e","order_by":6,"name":"Brent Neuschwander-Tetri","email":"","orcid":"https://orcid.org/0000-0002-8520-7398","institution":"Saint Louis University","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Brent","middleName":"","lastName":"Neuschwander-Tetri","suffix":""},{"id":169162501,"identity":"1d5e996c-4f4e-4c60-be7c-9dfdb045c815","order_by":7,"name":"Kris Kowdley","email":"","orcid":"","institution":"Liver Institute Northwest","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Kris","middleName":"","lastName":"Kowdley","suffix":""},{"id":169162502,"identity":"2b50cf46-a806-4dbc-8fe6-93a4602348d5","order_by":8,"name":"Raj Vuppalanchi","email":"","orcid":"","institution":"Indiana University School of Medicine","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Raj","middleName":"","lastName":"Vuppalanchi","suffix":""},{"id":169162503,"identity":"bc85d27c-c536-4228-8c6c-b31afc242e1f","order_by":9,"name":"Cynthia A. Behling","email":"","orcid":"","institution":"Sharp Memorial Hostipal","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Cynthia","middleName":"A.","lastName":"Behling","suffix":""},{"id":169162504,"identity":"6182e122-c9f1-4169-8e86-b3fd5eb4e28e","order_by":10,"name":"James Tonascia","email":"","orcid":"","institution":"Bloomberg School of Public Health, Johns Hopkins University","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"James","middleName":"","lastName":"Tonascia","suffix":""},{"id":169162505,"identity":"66115d88-07e8-4efe-a91a-249cce57ea43","order_by":11,"name":"Anthony Samir","email":"","orcid":"","institution":"Harvard School of Public Health","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Anthony","middleName":"","lastName":"Samir","suffix":""},{"id":169162506,"identity":"cb08c50c-6794-4d1c-95c9-9b21151b4273","order_by":12,"name":"Claude Sirlin","email":"","orcid":"https://orcid.org/0000-0002-6639-9072","institution":"","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Claude","middleName":"","lastName":"Sirlin","suffix":""},{"id":169162507,"identity":"8771c127-689f-494f-9f1d-cb848e2522bd","order_by":13,"name":"Sarah Sherlock","email":"","orcid":"","institution":"Pfizer","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Sarah","middleName":"","lastName":"Sherlock","suffix":""},{"id":169162508,"identity":"7ba9dd07-e048-41c9-8f15-50afea9711f1","order_by":14,"name":"Kathryn Fowler","email":"","orcid":"","institution":"University of California San Diego School of Medicine","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Kathryn","middleName":"","lastName":"Fowler","suffix":""},{"id":169162509,"identity":"0d1ade6b-6ef2-4a54-8249-730ca6f5e748","order_by":15,"name":"Helen Heymann","email":"","orcid":"","institution":"Foundation for the NIH","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Helen","middleName":"","lastName":"Heymann","suffix":""},{"id":169162510,"identity":"4ebd2be9-e07a-4b04-b853-e5413c6a1d28","order_by":16,"name":"Tania Kamphaus","email":"","orcid":"","institution":"Foundation for the NIH","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Tania","middleName":"","lastName":"Kamphaus","suffix":""},{"id":169162511,"identity":"3f53fb61-efa9-4a0f-8213-2d8accbf9ebc","order_by":17,"name":"Rohit Loomba","email":"","orcid":"https://orcid.org/0000-0002-4845-9991","institution":"University of California at San Diego","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Rohit","middleName":"","lastName":"Loomba","suffix":""},{"id":169162512,"identity":"35400be9-211b-414f-87f3-71c5401dc346","order_by":18,"name":"Roberto Calle","email":"","orcid":"https://orcid.org/0000-0001-6577-5657","institution":"Regeneron Pharmaceuticals","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Roberto","middleName":"","lastName":"Calle","suffix":""}],"badges":[],"createdAt":"2023-01-18 17:22:32","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-2492725/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-2492725/v1","draftVersion":[],"editorialEvents":[{"content":"https://doi.org/10.1038/s41591-023-02539-6","type":"published","date":"2023-09-07T04:00:00+00:00"}],"editorialNote":"","failedWorkflow":false,"files":[{"id":31829288,"identity":"1502bcb4-6dac-4365-98ce-464ec7cdfe9f","added_by":"auto","created_at":"2023-01-19 21:45:09","extension":"jpg","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":439548,"visible":true,"origin":"","legend":"\u003cp\u003eSample derivation from the NASH CRN cohort and their use for various tests\u003c/p\u003e\n\u003cp\u003eFootnotes: *NAS = NAFLD Activity Score\u003cbr\u003e\n †Subgroup definitions: 0=NAS\u0026lt;4, NAFL only, fibrosis stage\u0026lt;2; 1=NAS\u0026lt;4, any NASH, fibrosis stage\u0026lt;2; 3=NAS=4+, any NASH, fibrosis stage=2, 3; 3=cirrhosis\u003c/p\u003e","description":"","filename":"NIMBLE.FlowChart.22Jul22.jpg","url":"https://assets-eu.researchsquare.com/files/rs-2492725/v1/196176d7799fd3125345fdad.jpg"},{"id":31829290,"identity":"2dd5dd8a-3f8f-4b77-a15b-b9fe59d406c8","added_by":"auto","created_at":"2023-01-19 21:45:09","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":197130,"visible":true,"origin":"","legend":"\u003cp\u003eSensitivity and Specificity of key NIT panels for their respective intended uses are shown as a function of the cutoff scores for the NIT. The top panel demonstrate changes in sensitivity and specificity at varying NIS4 cutoff scores for the diagnosis of at-risk NASH (panel A) and its key subcomponent diagnosis of NASH (panel B) and stage 2 or greater fibrosis (Panel C). The middle panels show similar data for the ELF test for the diagnosis of ≥ stage 2 fibrosis (panel D), ≥stage 3 (panel E) and stage 4 i.e. cirrhosis (panel F). The lower panel demonstrates the changes in sensitivity and specificity at varying Fibrometer VCTE (FM-VCTE) score cutoffs for the diagnosis of ≥ stage 2 fibrosis (panel G), ≥ stage 3 fibrosis (panel H) and stage 4 fibrosis (panel I). Individual plots were derived from 50 individual score cutoffs covering the range where sensitivity was 100% to where specificity approached 100% followed by smoothening of the graph to cover the dynamic range of scores for their intended uses.\u003c/p\u003e","description":"","filename":"FigureFinal1.png","url":"https://assets-eu.researchsquare.com/files/rs-2492725/v1/aa47f3d8a9686d157a7f00ae.png"},{"id":43884986,"identity":"a3d33431-1fd3-4d02-a20c-c54c47b0a9ef","added_by":"auto","created_at":"2023-09-29 14:51:50","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":721350,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-2492725/v1/2cc720e4-df90-4e6b-9fb6-058ae3b23dc1.pdf"},{"id":31829289,"identity":"e9d149bb-e5f1-49b3-91f4-17f695c1419f","added_by":"auto","created_at":"2023-01-19 21:45:09","extension":"docx","order_by":2,"title":"","display":"","copyAsset":false,"role":"supplement","size":38683,"visible":true,"origin":"","legend":"","description":"","filename":"SupplementalTables.docx","url":"https://assets-eu.researchsquare.com/files/rs-2492725/v1/2898fa6f2570a71a4f0b5573.docx"}],"financialInterests":"\u003cb\u003eYes\u003c/b\u003e there is potential Competing Interest.\nthese are provided in the manuscript","formattedTitle":"\u003cp\u003eThe Nimble Stage 1 Study Validates Diagnostic Circulating Biomarkers for Nonalcoholic Steatohepatitis\u003c/p\u003e","fulltext":[{"header":"Introduction","content":"\u003cp\u003eNonalcoholic fatty liver disease (NAFLD) is a leading cause of liver-related morbidity and mortality \u003csup\u003e\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e\u003c/sup\u003e. The presence of nonalcoholic steatohepatitis (NASH) an active form of NAFLD and fibrosis stage of 2 or higher is linked to increased risk of liver outcomes and death \u003csup\u003e\u003cspan additionalcitationids=\"CR3\" citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e\u003c/sup\u003e. Identification of such individuals and targeting them for therapeutic intervention is a cornerstone of clinical assessment and inclusion in clinical trials \u003csup\u003e\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eHistological evaluation of liver biopsy sections is the reference standard for assessment of NASH but requires an invasive liver biopsy with its associated risks which has limited its widespread use \u003csup\u003e\u003cspan additionalcitationids=\"CR7\" citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e\u003c/sup\u003e. This has spurred much work to establish non-invasive tests (NITs) to diagnose NASH and fibrosis, yet none have met the evidence burden needed for regulatory approval. Validation of such NITs to regulatory standards remains a major unmet need for the field.\u003c/p\u003e \u003cp\u003eThe \u003cb\u003eN\u003c/b\u003eon-\u003cb\u003eI\u003c/b\u003envasive \u003cb\u003eB\u003c/b\u003eioMarkers of \u003cb\u003eM\u003c/b\u003eeta\u003cb\u003eB\u003c/b\u003eolic \u003cb\u003eL\u003c/b\u003eiver Diseas\u003cb\u003eE\u003c/b\u003e (NIMBLE) consortium was established by the Foundation-NIH (FNIH) to generate evidence to support advanced regulatory qualification of one or more NITs for the evaluation of nonalcoholic fatty liver disease (NAFLD) \u003csup\u003e\u003cb\u003e\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e\u003c/b\u003e\u003c/sup\u003e. The current study represents a collaborative effort between the NIMBLE consortium and the National Institute of Diabetes and Digestive and Kidney Diseases-NASH Clinical Research Network (CRN). The objective was to perform a cross-sectional study to rigorously define the sensitivity and specificity of five serum-based NIT panels for the diagnosis of one or more of the following: NASH, high histological NAFLD activity and subpopulations with clinically relevant stages of fibrosis including cirrhosis. The panels were pre-selected on the basis of their analytic robustness, available literature and potential for scale-up for widespread use. The final results of this study are presented below.\u003c/p\u003e"},{"header":"Materials And Methods","content":"\u003cp\u003eSerum samples collected from adult participants with NAFLD in a non-interventional registry (database 1 and 2 (DB1 and DB2) and baseline samples from clinical trials (PIVENS and FLINT) across 12 NIDDK NASH CRN clinical sites (\u003cem\u003esupplemental Table 1\u003c/em\u003e) were analyzed. \u0026nbsp;Participants were enrolled across these studies from 2004-2017 and provided informed consent at enrollment; the use of de-identified samples and meta-data was considered exempt from additional consenting requirements. \u0026nbsp;The investigators have analyzed the data and take responsibility for the contents of this manuscript. \u0026nbsp;The studies were done in accordance to STARD guidance and reported using the TRIPOD statement\u0026nbsp;\u003csup\u003e10,11\u003c/sup\u003e.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eContext of Use\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eIn individuals with NAFLD or with risk-factors for NAFLD, to serve as a diagnostic enrichment tool for the identification of various histological phenotypes of NAFLD, intended for selection for participation in NAFLD/NASH clinical trials and/or drug treatment. \u0026nbsp;Those who were overweight or obese, or had other features of metabolic syndrome were considered to be at risk for NAFLD\u0026nbsp;\u003csup\u003e12\u003c/sup\u003e. \u0026nbsp;The presence of specific phenotypes to be diagnosed included:\u003c/p\u003e\n\u003cul\u003e\n \u003cli\u003eAt risk NASH: (NASH + NAFLD activity score (NAS) \u0026ge; 4 + fibrosis stage 2 or higher)\u003csup\u003e9\u003c/sup\u003e\u003c/li\u003e\n \u003cli\u003eNonalcoholic steatohepatitis (borderline or definite)\u003c/li\u003e\n \u003cli\u003eA NAS \u0026ge; 4\u003c/li\u003e\n \u003cli\u003eClinically significant fibrosis (fibrosis stage \u0026ge; 2)\u003c/li\u003e\n \u003cli\u003eAdvanced fibrosis (stage 3 or 4)\u003c/li\u003e\n \u003cli\u003eCirrhosis (stage 4)\u003c/li\u003e\n\u003c/ul\u003e\n\u003cp\u003e\u003cstrong\u003eStudy Design\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;\u003cstrong\u003eA: Study population\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe study population was curated from the CRN patient base to ensure sufficient number of individuals with and without the histological phenotypes of interest and a balanced distribution of fibrosis stages to avoid spectrum bias. \u0026nbsp;The current analysis included aliquots from a serum-sample obtained within 90-180 days of an evaluable liver biopsy demonstrating NAFLD. For Fibrometer VCTE (vibration-controlled transient elastography), a liver stiffness measurement was required within 180 days of the biopsy. \u0026nbsp;Exclusion criteria included pregnancy at the time of sample collection or biopsy, co-morbid liver diseases, use of drugs known to cause steatosis, non-availability of minimum required serum, bariatric surgery within 3 years prior to biopsy, prior liver transplant and known primary or secondary malignancy of the liver. \u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;\u003cstrong\u003eB: Biomarker panels tested and their intended context of use\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eSerum biomarker panels selected by the NIMBLE circulating workstream were reviewed and approved by the project team, NASH CRN ancillary study and steering committees. These included:\u003c/p\u003e\n\u003cp\u003eNIS4\u003csup\u003e13\u003c/sup\u003e: \u0026nbsp;mir34a, Hemoglobin A1c,\u0026nbsp;\u0026alpha;2-macroglobulin, YKL-40\u003c/p\u003e\n\u003cp\u003eOWliver\u003csup\u003e14\u003c/sup\u003e: triglyceride species with variable number of saturated fatty acids\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eELF test\u003csup\u003e15\u003c/sup\u003e: \u0026nbsp;type III procollagen peptide, hyaluronic acid and TIMP-1\u003c/p\u003e\n\u003cp\u003ePROC3\u003csup\u003e16\u003c/sup\u003e: procollagen-3 fragment reflective of fibrogenesis\u003c/p\u003e\n\u003cp\u003eFibrometer VCTE\u0026nbsp;\u003csup\u003e17\u003c/sup\u003e:\u0026nbsp;LSM, age, gender, \u0026alpha;2-macroglobulin, INR, platelet count, AST, GGT\u003c/p\u003e\n\u003cp\u003eThe intended use of NIS4 was to diagnose at-risk NASH and its components whereas the OWliver panels intended use was to diagnose the presence of NASH (\u003cem\u003esupplemental Table 2\u003c/em\u003e). \u0026nbsp;The intended uses of the ELF test, PROC3 and Fibrometer VCTE were to diagnose clinically significant fibrosis (\u0026ge;\u0026nbsp;stage 2 fibrosis), advanced fibrosis (\u0026ge;\u0026nbsp;stage 3 fibrosis) or cirrhosis (stage 4 fibrosis).\u003c/p\u003e\n\u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;C: \u003cstrong\u003eStudy Approach\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe study plan was summarized in a letter of intent approved by the US federal government Food and Drug Administration\u0026nbsp;\u003csup\u003e9,18\u003c/sup\u003e. De-identified, bar-coded frozen aliquots of the same serum sample from each participant without any prior freeze-thaw were released to the individual laboratories. \u0026nbsp;These laboratories generated panel scores which were provided to the independent statistical team (Cytel) who deposited these in the CRN data warehouse. The CRN then released the meta-data linked to the bar codes to Cytel who implemented the prespecified statistical analysis plan without involvement of individual vendors whose panels were tested. \u0026nbsp;The NIMBLE circulating workstream and statistical team then jointly reviewed the results and interpreted the data.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eD: Histological Examination:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe pathology committee of the NASH CRN performed the histological assessment, masked to clinical and laboratory data, using an established and validated protocol \u0026nbsp;\u003csup\u003e19,20\u003c/sup\u003e. \u0026nbsp;The key measures included the presence of steatohepatitis and individual severity grades for steatosis (0-3), lobular inflammation (0-2), hepatocellular ballooning (0-2) and fibrosis stage (0-4). \u0026nbsp;The NAS was computed from the scores for steatosis, ballooning and inflammation while \u0026ldquo;at risk\u0026rdquo; NASH was computed from the presence of its components\u0026nbsp;\u003csup\u003e9,20\u003c/sup\u003e.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eStatistical Plan\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThere were two pre-specified performance metrics which formed the basis for hypothesis-testing. First, that the area under receiver operating curve (AUROC) for each panel would be 0.7 or higher for its intended use with 95% confidence limits that would not intersect 0.5. \u0026nbsp;Next, the biomarker performance would be superior to commonly used blood-based laboratory aids for their intended use. \u0026nbsp;The AUROC of each panel was therefore compared to that of ALT for diagnosis of NASH or NAS\u0026ge;\u0026nbsp;4 and FIB-4, a commonly used laboratory aid based on age, AST, ALT and platelet counts, for diagnosis of fibrosis severity\u0026nbsp;\u003csup\u003e21,22\u003c/sup\u003e. \u0026nbsp;The sensitivity and specificity were computed at the Youden cut-point. The sensitivity was further estimated keeping specificity fixed at 90% and conversely specificity was measured keeping the sensitivity fixed at 90%. \u0026nbsp;Finally, the positive and negative predictive values were computed at various prevalence of specific NAFLD phenotypes. Missing data were assumed missing at random from the statistical analysis, as they resulted from sample handling and laboratory issues independent of the relationship between biomarkers and histology; complete case-analysis was done.\u003c/p\u003e\n\u003cp\u003eThe sample size was estimated to detect a difference of at least 0.05 between the AUROC of FIB-4 or ALT and the relevant biomarker panel with a power of at least 80% with a one-sided p value of 0.025. \u0026nbsp;It was assumed that the AUROC for FIB-4 would be 0.8 for fibrosis. \u0026nbsp;Additionally, due to potential correlation between FIB-4 or ALT versus the biomarker panels, adjustments were made assuming the correlation coefficients ranging from 0.5-0.8. \u0026nbsp;Based on these a total number of participants needed with NASH and fibrosis stage 2 or 3 versus 0 or 1 was 400 each. \u0026nbsp;For analysis of cirrhosis, 180 individuals with cirrhosis were needed. \u0026nbsp;\u003c/p\u003e"},{"header":"Results","content":"\u003cp\u003eThe NASH CRN cohort had 4094 participants \u003cstrong\u003e(Figure 1)\u003c/strong\u003e. \u0026nbsp;A total of 2479 individuals were excluded because of age, lack of samples or evaluable liver biopsies. \u0026nbsp;Of the remaining individuals, consecutive patients for each stage of disease were selected to ensure that that enough patients were available to meet sample size estimates and to have a relatively balanced-distributed spectrum of fibrosis severity (stages 0-4, n= 222, 114, 262, 277 and 198 respectively). \u0026nbsp;A total of 1073 individuals meeting eligibility criteria were thus included for this analysis with 90% of individuals having a serum sample within 90 days of the liver biopsy \u003cstrong\u003e(Table 1)\u003c/strong\u003e. \u0026nbsp;\u003c/p\u003e\n\u003cp\u003eThe mean age of the cohort was 54 years and was preponderantly female and white. \u0026nbsp;NAFL was present in 225 individuals while 835 had NASH and 13 an indeterminate NAFLD phenotype. \u0026nbsp;Those without fibrosis were younger, had mainly had NAFL and lower NAS compared to those with fibrosis stage 2 or higher. The study population for Fibrometer VCTE was a smaller subset of the larger population (n= 396) for this analysis due to lack of availability of a VCTE examination within 6 months of the liver biopsy in many individuals. \u0026nbsp;The baseline features of this subset were similar to the larger cohort (\u003cem\u003esupplemental Table 3\u003c/em\u003e).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAt-risk NASH\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNIS4 was the only panel with an intended use to diagnose underlying composite phenotype of \u0026ldquo;at risk\u0026rdquo; NASH (n=539) as defined above. \u0026nbsp;The sensitivity and specificity were 78.1% and 73.6% respectively with an AUROC of 0.815 at the optimal cut-point \u003cstrong\u003e(Table 2)\u003c/strong\u003e. \u0026nbsp;The AUROC was superior (p\u0026lt; 0.001 for both) to both ALT (AUROC 0.726) and FIB-4 (AUROC 0.704).\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eNASH Diagnosis\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNIS4 and the OWLiver tests had an intended use to diagnose NASH (\u003cem\u003esupplemental Table 2\u003c/em\u003e). \u0026nbsp;NIS4 (Youden cut-point 0.539) had an AUROC of 0.83 (95% CI 0.8-0.86) and was superior to ALT (AUROC 0.67) for this intended use \u003cstrong\u003e(Table 2, Figure 2)\u003c/strong\u003e. \u0026nbsp;The sensitivity and specificity were 77.7% and 76.2% respectively at this cut-point. \u0026nbsp;NIS4 had a specificity of 47.7% and sensitivity of 54.4% when sensitivity and specificity were constrained at 90% respectively (\u003cem\u003esupplemental table 4\u003c/em\u003e) and both were significantly superior to ALT (p\u0026lt;0.001 for both). The OWLiver provided the results in categorical format which did not permit generation of an AUROC; it diagnosed NASH with a sensitivity of 77.3%. and specificity of 66.8%. \u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eHigh NAFLD Activity Score (NAS\u0026nbsp;\u003c/strong\u003e\u003cstrong\u003e\u0026ge;\u003c/strong\u003e\u003cstrong\u003e\u0026nbsp;4)\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe AUROC (0.815, 95% CI 0.786-0.844) for NIS4 was significantly superior to ALT (AUROC 0.726, sensitivity 71.1%, specificity 64.1%) the comparator for panels intended to diagnose high activity (p\u0026lt;0.001). \u0026nbsp;The specificity and sensitivity of NIS4 were 57.8% and 46.2% when sensitivity and specificity were locked at 90% respectively and both were significantly superior to ALT (p\u0026lt; 0.001 for both).\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eClinically significant fibrosis (Fibrosis stage\u0026nbsp;\u003c/strong\u003e\u003cstrong\u003e\u0026ge;\u003c/strong\u003e\u003cstrong\u003e\u0026nbsp;2):\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNIS4, ELF, PROC3 and Fibrometer VCTE had an intended use to identify clinically significant fibrosis in those with NAFLD. \u0026nbsp;The AUROCs of NIS4, ELF, PROC3 and Fibrometer VCTE were 0.874, 0.828, 0.8 and 0.841 respectively. \u0026nbsp;Their respective sensitivity and specificity at their Youden index are provided in Table 2. \u0026nbsp;FIB-4 had an AUROC of 0.798 very close to the expected AUROC of 0.8\u0026nbsp;\u003csup\u003e22\u003c/sup\u003e. \u0026nbsp;NIS4 (p\u0026lt; 0.001), ELF (p\u0026lt; 0.01) and Fibrometer VCTE (p\u0026lt; 0.001) were all superior to FIB4. \u0026nbsp;Similar data were obtained when the performance of these panels with sensitivity and specificity constrained at 90% were evaluated (\u003cem\u003esupplemental Table 4\u003c/em\u003e).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAdvanced fibrosis (Stages\u0026nbsp;\u003c/strong\u003e\u003cstrong\u003e\u0026ge;\u003c/strong\u003e\u003cstrong\u003e\u0026nbsp;3):\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe operational definition of advanced fibrosis included those with stage 3 or 4. The AUROCs of the panels tested for the diagnosis of advanced fibrosis were as follows: FIB-4 (0.789), ELF (0.835, p\u0026lt;0.001 vs FIB4), PROC3 (0.809, p=n.s. vs FIB-4), Fibrometer VCTE (0.841, p\u0026lt; 0.001 vs FIB4). A secondary analysis of NIS-4 for advanced fibrosis provided an AUROC of 0.78, p=n.s. vs FIB4). \u0026nbsp;The sensitivity (ELF 50.3% and Fibrometer VCTE 54.2%) and specificity (ELF 55.3% and Fibrometer VCTE 59.6%) with specificity and sensitivity fixed at 90% respectively were both statistically superior to FIB-4 (\u003cem\u003esupplemental Table 4\u003c/em\u003e).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCirrhosis (stage 4)\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe AUROCs for the diagnosis of cirrhosis were 0.81 for FIB-4, 0.855 for ELF (p\u0026lt; 0.001 vs FIB-4) and 0.897 for Fibrometer VCTE (p=0.002 vs FIB-4). The sensitivity of ELF and Fibrometer VCTE at the Youden index were 82.1% and 94.2% while the specificities were 73.3% and 70.4% respectively. Their performance at 90% sensitivity (specificity: ELF 60.5%, Fibrometer VCTE 72.5%) and 90% specificity (Sensitivity: ELF 49%, Fibrometer VCTE: 66.7%) were also statistically superior to FIB-4 (\u003cem\u003eSupplemental Table 4\u003c/em\u003e).\u003c/p\u003e"},{"header":"Discussion","content":"\u003cp\u003eThe regulatory path for approval of a diagnostic test requires rigorously established sensitivity and specificity in a study cohort that is both powered and balanced with respect to the presence or absence of the condition being studied. The current study establishes this first step and is the foundation for the use of specific cut-points in relevant populations in the next stage towards regulatory approval of these diagnostic enrichment tools for NASH\u003csup\u003e\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eThe study has several methodological strengths. The time from biopsy to blood draw was short and all analyses including the comparators were made on the same blood sample. Further, all samples were drawn, aliquoted, stored and analyzed without multiple freeze-thaw using prespecified protocols. Histology was read independently using a rigorous pre-specified protocol by the pathology committee of the NASH CRN masked to clinical and laboratory data. The distribution of fibrosis stages in the cohort avoided spectrum bias. Finally, for each of the phenotypes studied, the sample size included enough number of individuals with and without the phenotype assuring power both for sensitivity and specificity.\u003c/p\u003e \u003cp\u003eThe practical application of these data has to be considered in the context of how the tests are used. In primary care where the prevalence of advanced fibrosis is 1%, positive tests are likely to be false positives and even with excellent sensitivity and specificity the PPV will be low \u003csup\u003e\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e\u003c/sup\u003e. Using these tests to identify patients for clinical trials in such settings are likely to have many false positives resulting in high screen fail rates. The NPV for FIB4 as well as all of the biomarker panels (ranged from 98-99.7% when the population prevalence of advanced fibrosis was 1% (\u003cem\u003esupplemental Table\u0026nbsp;5\u003c/em\u003e). These tests can therefore be applied for exclusion of this phenotype for both clinical management and for screening for trials of at-risk NASH in a primary care setting.\u003c/p\u003e \u003cp\u003eThe prevalence of at-risk NASH or its subsets NASH with advanced fibrosis or cirrhosis in hepatology clinic settings are higher and range from 10\u0026ndash;40% \u003csup\u003e2,12,24\u003c/sup\u003e. It is encouraging to note that the high NPV in settings with low prevalence was maintained at these ranges while the positive predictive values approached 80% at the 40% prevalence when the Youden cut point was used (\u003cem\u003esupplemental Table\u0026nbsp;5\u003c/em\u003e). In clinical trial settings, these data should allow exclusion of those without these phenotypes while limiting overdiagnosis compared to a primary care setting. Additional enhancement of certainty for ruling in disease by using the cut point for 90% specificity will however be associated with a loss of sensitivity and attendant misclassification.\u003c/p\u003e \u003cp\u003eFurther improvement is likely to require an algorithmic approach using multiple panels or use of imaging-based tests for greater precision in identification of this population. Recently, MR-elastography with FIB4 or AST has been shown to identify those with NASH and advanced fibrosis or at-risk NASH respectively and may provide such tools \u003csup\u003e\u003cspan additionalcitationids=\"CR26\" citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e\u003c/sup\u003e. The current data can\u0026rsquo;t however be directly compared to these due to methodological differences.\u003c/p\u003e \u003cp\u003eFor those with advanced fibrosis or cirrhosis, a mistaken diagnosis of absence of these phenotypes may cause patients to be followed without surveillance for hepatocellular cancer or varices. The overall high NPVs suggest that the risks are in general low. Conversely, overdiagnosis due to the modest PPVs may result in futile additional testing including liver biopsies with its attendant risks. ELF and Fibrometer VCTE can identify 82\u0026ndash;94% of true positive cases of cirrhosis but also may over-diagnose some patients to have cirrhosis in clinics with high prevalence of cirrhosis (Table\u0026nbsp;5). The risks of overdiagnosis has to be considered in the context of the risks of missing advanced fibrosis or cirrhosis altogether in specific populations both in clinical practice and for consideration for inclusion in trials.\u003c/p\u003e \u003cp\u003eThis study also has some limitations. The NASH CRN is based at tertiary care centers generating ascertainment bias. The study population is predominantly white and the data are not generalizable to other races. Despite these limitations, the current study provides a rigorous evidence base to establish the sensitivity and specificity of these biomarker panels serves as a critical step in the ultimate regulatory approval of some of these panels as diagnostic enrichment tools in clinical practice and to determine eligibility for inclusion in clinical trials for NASH.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003eEstes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology (Baltimore, Md 2018;67(1):123\u0026ndash;133. (Review Research Support, Non-U.S. Gov't) (In eng). DOI: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1002/hep.29466\u003c/span\u003e\u003cspan address=\"10.1002/hep.29466\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKleiner DE, Brunt EM, Wilson LA, et al. Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease. JAMA network open 2019;2(10):e1912565. (In eng). DOI: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1001/jamanetworkopen.2019.12565\u003c/span\u003e\u003cspan address=\"10.1001/jamanetworkopen.2019.12565\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSanyal AJ, Van Natta ML, Clark J, et al. Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease. The New England journal of medicine 2021;385(17):1559\u0026ndash;1569. DOI: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1056/NEJMoa2029349\u003c/span\u003e\u003cspan address=\"10.1056/NEJMoa2029349\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDulai PS, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. Hepatology (Baltimore, Md 2017;65(5):1557\u0026ndash;1565. (Meta-Analysis Review) (In eng). DOI: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1002/hep.29085\u003c/span\u003e\u003cspan address=\"10.1002/hep.29085\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eFDA. Noncirrhotic Nonalcoholic Steatohepatitis With Liver Fibrosis: Developing Drugs for Treatment Guidance for Industry. US Food and Drug Administration; 2018.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRinella ME, Lominadze Z, Loomba R, et al. Practice patterns in NAFLD and NASH: real life differs from published guidelines. Therapeutic advances in gastroenterology 2016;9(1):4\u0026ndash;12. (In eng). DOI: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1177/1756283X15611581\u003c/span\u003e\u003cspan address=\"10.1177/1756283X15611581\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSanyal AJ. Past, present and future perspectives in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2019;16(6):377\u0026ndash;386. (Research Support, N.I.H., Extramural Review) (In eng). DOI: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/s41575-019-0144-8\u003c/span\u003e\u003cspan address=\"10.1038/s41575-019-0144-8\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD, American Association for the Study of Liver D. Liver biopsy. Hepatology (Baltimore, Md 2009;49(3):1017\u0026ndash;44. (Practice Guideline) (In eng). DOI: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1002/hep.22742\u003c/span\u003e\u003cspan address=\"10.1002/hep.22742\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSanyal AJ, Shankar SS, Calle RA, et al. Non-Invasive Biomarkers of Nonalcoholic Steatohepatitis: the FNIH NIMBLE project. Nature medicine 2022. DOI: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/s41591-021-01652-8\u003c/span\u003e\u003cspan address=\"10.1038/s41591-021-01652-8\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCollins GS, Reitsma JB, Altman DG, Moons KG. Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD). Annals of internal medicine 2015;162(10):735\u0026ndash;6. (Comment Letter) (In eng). DOI: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.7326/L15-5093-2\u003c/span\u003e\u003cspan address=\"10.7326/L15-5093-2\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBossuyt PM, Reitsma JB, Bruns DE, et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Annals of internal medicine 2003;138(1):W1-12. (In eng) (\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve\u003c/span\u003e\u003cspan address=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u0026amp;db=PubMed\u0026amp;dopt=Citation\u0026amp;list_uids=12513067).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eChalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology (Baltimore, Md 2018;67(1):328\u0026ndash;357. (Practice Guideline Research Support, Non-U.S. Gov't Review) (In eng). DOI: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1002/hep.29367\u003c/span\u003e\u003cspan address=\"10.1002/hep.29367\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHarrison SA, Ratziu V, Boursier J, et al. A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study. The lancet Gastroenterology \u0026amp; hepatology 2020 (In eng). DOI: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/S2468-1253(20)30252-1\u003c/span\u003e\u003cspan address=\"10.1016/S2468-1253(20)30252-1\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMayo R, Crespo J, Martinez-Arranz I, et al. Metabolomic-based noninvasive serum test to diagnose nonalcoholic steatohepatitis: Results from discovery and validation cohorts. Hepatology communications 2018;2(7):807\u0026ndash;820. (In eng). DOI: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1002/hep4.1188\u003c/span\u003e\u003cspan address=\"10.1002/hep4.1188\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGuha IN, Parkes J, Roderick P, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology (Baltimore, Md 2008;47(2):455\u0026ndash;60. (In eng) (\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve\u003c/span\u003e\u003cspan address=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u0026amp;db=PubMed\u0026amp;dopt=Citation\u0026amp;list_uids=18038452).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLuo Y, Oseini A, Gagnon R, et al. An Evaluation of the Collagen Fragments Related to Fibrogenesis and Fibrolysis in Nonalcoholic Steatohepatitis. Scientific reports 2018;8(1):12414. (Research Support, N.I.H., Extramural) (In eng). DOI: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/s41598-018-30457-y\u003c/span\u003e\u003cspan address=\"10.1038/s41598-018-30457-y\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCales P, Boursier J, Oberti F, et al. FibroMeters: a family of blood tests for liver fibrosis. Gastroenterologie clinique et biologique 2008;32(6 Suppl 1):40\u0026ndash;51. (In eng) (\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve\u003c/span\u003e\u003cspan address=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u0026amp;db=PubMed\u0026amp;dopt=Citation\u0026amp;list_uids=18973845).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDDTBMQ000084. Circulating Biomarkers for Diagnosis of Nonalcoholic steatohepatitis (NASH). 2020.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKleiner DE, Brunt EM. Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research. Seminars in liver disease 2012;32(1):3\u0026ndash;13. (Research Support, N.I.H., Intramural Review) (In Eng). DOI: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1055/s-0032-1306421\u003c/span\u003e\u003cspan address=\"10.1055/s-0032-1306421\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology (Baltimore, Md 2005;41(6):1313\u0026ndash;21. (Multicenter Study Research Support, N.I.H., Extramural Research Support, U.S. Gov't, P.H.S. Validation Studies) (In eng). DOI: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1002/hep.20701\u003c/span\u003e\u003cspan address=\"10.1002/hep.20701\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology (Baltimore, Md 2006;43(6):1317-25. (Comparative Study Research Support, N.I.H., Extramural) (In eng). DOI: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1002/hep.21178\u003c/span\u003e\u003cspan address=\"10.1002/hep.21178\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eShah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009;7(10):1104-12. (Comparative Study Evaluation Studies Research Support, N.I.H., Extramural) (In eng). DOI: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.cgh.2009.05.033\u003c/span\u003e\u003cspan address=\"10.1016/j.cgh.2009.05.033\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHuber Y, Schulz A, Schmidtmann I, et al. Prevalence and Risk Factors of Advanced Liver Fibrosis in a Population-Based Study in Germany. Hepatology communications 2022;6(6):1457\u0026ndash;1466. DOI: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1002/hep4.1899\u003c/span\u003e\u003cspan address=\"10.1002/hep4.1899\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMatteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116(6):1413\u0026ndash;9. (In eng) (\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve\u003c/span\u003e\u003cspan address=\"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u0026amp;db=PubMed\u0026amp;dopt=Citation\u0026amp;list_uids=10348825).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKim BK, Tamaki N, Imajo K, et al. Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD. Journal of hepatology 2022. DOI: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.jhep.2022.07.020\u003c/span\u003e\u003cspan address=\"10.1016/j.jhep.2022.07.020\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eJung J, Loomba RR, Imajo K, et al. MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis. Gut 2021;70(10):1946\u0026ndash;1953. DOI: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1136/gutjnl-2020-322976\u003c/span\u003e\u003cspan address=\"10.1136/gutjnl-2020-322976\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAjmera V, Kim BK, Yang K, et al. Liver Stiffness on Magnetic Resonance Elastography and the MEFIB Index and Liver-Related Outcomes in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Individual Participants. Gastroenterology 2022. DOI: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1053/j.gastro.2022.06.073\u003c/span\u003e\u003cspan address=\"10.1053/j.gastro.2022.06.073\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"},{"header":"Tables","content":"\u003ch2 style='margin-top:2.0pt;margin-right:0in;margin-bottom:6.0pt;margin-left:0in;line-height:107%;font-size:16px;font-family:\"Times New Roman\",serif;color:#2F5496;'\u003eTable 1: \u0026nbsp;Demographic, Clinical and Laboratory Data from the Study Cohort\u003c/h2\u003e\n\u003ctable style=\"border-collapse:collapse;border:none;\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:131.4pt;border:solid windowtext 1.0pt;border-bottom: none;padding:0in 5.4pt 0in 5.4pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cstrong\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cstrong\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;'\u003eStage 0\u003c/span\u003e\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cstrong\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;'\u003eStage 1\u003c/span\u003e\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.25pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cstrong\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;'\u003eStage 2\u003c/span\u003e\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cstrong\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;'\u003eStage 3\u003c/span\u003e\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.25pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cstrong\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;'\u003eStage 4\u003c/span\u003e\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:131.4pt;border:solid windowtext 1.0pt;border-top: none;padding:0in 5.4pt 0in 5.4pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cstrong\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border-top:none;border-left:none;border-bottom: solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding: 0in 5.4pt 0in 5.4pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cstrong\u003e\u003cspan style='font-size:13px;line-height: 107%;font-family:\"Times New Roman\",serif;color:black;'\u003eN = 222\u003c/span\u003e\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border-top:none;border-left:none;border-bottom: solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding: 0in 5.4pt 0in 5.4pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cstrong\u003e\u003cspan style='font-size:13px;line-height: 107%;font-family:\"Times New Roman\",serif;color:black;'\u003eN = 114\u003c/span\u003e\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.25pt;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cstrong\u003e\u003cspan style='font-size:13px;line-height: 107%;font-family:\"Times New Roman\",serif;color:black;'\u003eN = 262\u003c/span\u003e\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border-top:none;border-left:none;border-bottom: solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding: 0in 5.4pt 0in 5.4pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cstrong\u003e\u003cspan style='font-size:13px;line-height: 107%;font-family:\"Times New Roman\",serif;color:black;'\u003eN = 277\u003c/span\u003e\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.25pt;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cstrong\u003e\u003cspan style='font-size:13px;line-height: 107%;font-family:\"Times New Roman\",serif;color:black;'\u003eN = 198\u003c/span\u003e\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:131.4pt;border-top:none;border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;padding: 0in 5.4pt 0in 5.4pt;height:12.25pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family: \"Times New Roman\",serif;'\u003eAge (years)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.25pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e47.8 (12.2)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.25pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e48.1 (13.8)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.25pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.25pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e51.7 (11.5)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.25pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e54.4 (11.2)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.25pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.25pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e56.2 (9.8)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:131.4pt;border:solid windowtext 1.0pt;border-top: none;padding:0in 5.4pt 0in 5.4pt;height:12.25pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family: \"Times New Roman\",serif;'\u003eGender (males) [n (%)]\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border-top:none;border-left:none;border-bottom: solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding: 0in 5.4pt 0in 5.4pt;height:12.25pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e99 (44.6%)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border-top:none;border-left:none;border-bottom: solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding: 0in 5.4pt 0in 5.4pt;height:12.25pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e52 (45.6%)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.25pt;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.25pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e102 (38.9%)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border-top:none;border-left:none;border-bottom: solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding: 0in 5.4pt 0in 5.4pt;height:12.25pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e91 (32.9%)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.25pt;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.25pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e60 (30.3%)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:131.4pt;border-top:none;border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;padding: 0in 5.4pt 0in 5.4pt;height:12.25pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family: \"Times New Roman\",serif;'\u003eWhite [n (%)]\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.25pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e158 (71.2%)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.25pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e68 (59.6%)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.25pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.25pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e199 (76.2%)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.25pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e217 (78.9%)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.25pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.25pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e169 (86.2%)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:131.4pt;border-top:none;border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;padding: 0in 5.4pt 0in 5.4pt;height:12.25pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family: \"Times New Roman\",serif;'\u003eAfrican American [n (%)]\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.25pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e4 (1.8%)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.25pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e5 (4.4%)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.25pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.25pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e8 (3.1%)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.25pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e8 (2.9%)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.25pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.25pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e3 (1.5%)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:131.4pt;border-top:none;border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;padding: 0in 5.4pt 0in 5.4pt;height:12.25pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family: \"Times New Roman\",serif;'\u003eHispanic [n (%)]\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.25pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e34 (15.3%)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.25pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e20 (17.5%)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.25pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.25pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e28 (10.7%)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.25pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e24 (8.7%)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.25pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.25pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e16 (8.2%)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:131.4pt;border:solid windowtext 1.0pt;border-top: none;padding:0in 5.4pt 0in 5.4pt;height:12.25pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family: \"Times New Roman\",serif;'\u003eOther [n (%)]\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border-top:none;border-left:none;border-bottom: solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding: 0in 5.4pt 0in 5.4pt;height:12.25pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e26 (11.7%)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border-top:none;border-left:none;border-bottom: solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding: 0in 5.4pt 0in 5.4pt;height:12.25pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e21 (18.4%)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.25pt;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.25pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e26 (10.0%)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border-top:none;border-left:none;border-bottom: solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding: 0in 5.4pt 0in 5.4pt;height:12.25pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e26 (9.5%)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.25pt;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.25pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e8 (4.1%)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:131.4pt;border-top:none;border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;padding: 0in 5.4pt 0in 5.4pt;height:12.25pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family: \"Times New Roman\",serif;'\u003eBMI (kg/m\u003csup\u003e2\u003c/sup\u003e)\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.25pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e32.8 (6.6)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.25pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e33.3 (6.1)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.25pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.25pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e34.5 (6.3)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.25pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e36.1 (6.6)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.25pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.25pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e36.4 (7.3)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:131.4pt;border-top:none;border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;padding: 0in 5.4pt 0in 5.4pt;height:12.25pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family: \"Times New Roman\",serif;'\u003eWaist circ (cm)\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.25pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e104.7 (14.7)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.25pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e107.3 (13.9)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.25pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.25pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e110.8 (14.2)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.25pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e114.3 (14.8)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.25pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.25pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e113.7 (15.1)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:131.4pt;border-top:none;border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;padding: 0in 5.4pt 0in 5.4pt;height:12.25pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family: \"Times New Roman\",serif;'\u003eType 2 diabetes [n (%)]\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.25pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e45 (20.3%)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.25pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e41 (36.0%)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.25pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.25pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e113 (43.1%)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.25pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e162 (58.5%)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.25pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.25pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e129 (65.2%)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:131.4pt;border:solid windowtext 1.0pt;border-top: none;padding:0in 5.4pt 0in 5.4pt;height:12.25pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family: \"Times New Roman\",serif;'\u003eHypertension [n (%)]\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border-top:none;border-left:none;border-bottom: solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding: 0in 5.4pt 0in 5.4pt;height:12.25pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e94 (42.3%)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border-top:none;border-left:none;border-bottom: solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding: 0in 5.4pt 0in 5.4pt;height:12.25pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e65 (57.0%)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.25pt;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.25pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e164 (62.6%)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border-top:none;border-left:none;border-bottom: solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding: 0in 5.4pt 0in 5.4pt;height:12.25pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e191 (69.0%)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.25pt;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.25pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e132 (66.7%)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:131.4pt;border-top:none;border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;padding: 0in 5.4pt 0in 5.4pt;height:12.25pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family: \"Times New Roman\",serif;'\u003eAST (IU/L)\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.25pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e27.8 (13.3)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.25pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e31.9 (17.7)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.25pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.25pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e50.3 (29.3)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.25pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e58.3 (39.8)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.25pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.25pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e51.9 (28.9)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:131.4pt;border-top:none;border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;padding: 0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family: \"Times New Roman\",serif;'\u003eALT (IU/L)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e38.5 (25.4)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e45.0 (34.6)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.25pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e65.5 (43.1)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e68.1 (47.8)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.25pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e49.1 (34.5)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:131.4pt;border-top:none;border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;padding: 0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family: \"Times New Roman\",serif;'\u003eALP (IU/L)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e86.6 (30.5)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e80.6 (28.2)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.25pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e87.0 (28.0)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e93.0 (33.2)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.25pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e114.5 (53.2)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:131.4pt;border-top:none;border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;padding: 0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family: \"Times New Roman\",serif;'\u003eTotal Bilirubin (mg/dL)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e0.5 (0.3)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e0.6 (0.5)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.25pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e0.5 (0.3)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e0.5 (0.4)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.25pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e0.8 (0.8)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:131.4pt;border-top:none;border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;padding: 0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family: \"Times New Roman\",serif;'\u003eINR\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e1.0 (0.1)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e1.0 (0.2)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.25pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e1.0 (0.1)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e1.1 (0.1)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.25pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e2.8 (4.3)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:131.4pt;border:solid windowtext 1.0pt;border-top: none;padding:0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family: \"Times New Roman\",serif;'\u003eAlbumin (g/dL)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border-top:none;border-left:none;border-bottom: solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding: 0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e4.6 (0.3)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border-top:none;border-left:none;border-bottom: solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding: 0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e4.6 (0.3)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.25pt;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e4.6 (0.3)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border-top:none;border-left:none;border-bottom: solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding: 0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e4.5 (0.3)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.25pt;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e4.3 (0.4)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:131.4pt;border-top:none;border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;padding: 0in 5.4pt 0in 5.4pt;height:2.5pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family: \"Times New Roman\",serif;'\u003eHemoglobin (g/dL)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:2.5pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e14.4 (1.4)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:2.5pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e14.3 (1.5)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.25pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:2.5pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e14.2 (1.5)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:2.5pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e13.9 (1.5)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.25pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:2.5pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e13.6 (1.6)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:131.4pt;border-top:none;border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;padding: 0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family: \"Times New Roman\",serif;'\u003eWBC (10\u003csup\u003e3\u003c/sup\u003e/\u0026micro;L)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e7.0 (2.2)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e7.1 (2.0)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.25pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e7.3 (2.0)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e7.6 (6.0)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.25pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e6.5 (3.3)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:131.4pt;border:solid windowtext 1.0pt;border-top: none;padding:0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family: \"Times New Roman\",serif;'\u003ePlatelet (cells/mL)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border-top:none;border-left:none;border-bottom: solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding: 0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e250.3 (62.7)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border-top:none;border-left:none;border-bottom: solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding: 0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e243.5 (82.9)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.25pt;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e237.8 (60.5)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border-top:none;border-left:none;border-bottom: solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding: 0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e218.7 (66.2)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.25pt;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e165.9 (64.1)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:131.4pt;border-top:none;border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;padding: 0in 5.4pt 0in 5.4pt;height:12.25pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family: \"Times New Roman\",serif;'\u003eFasting glucose (mg/dL)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.25pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e101.3 (33.8)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.25pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e106.7 (42.0)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.25pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.25pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e114.6 (42.2)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.25pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e116.6 (34.8)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.25pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.25pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e126.2 (51.7)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:131.4pt;border-top:none;border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;padding: 0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family: \"Times New Roman\",serif;'\u003eFasting insulin (\u0026micro;U/mL)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e17.8 (14.2)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e25.5 (32.4)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.25pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e26.8 (29.1)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e30.9 (27.6)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.25pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e35.5 (35.4)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:131.4pt;border-top:none;border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;padding: 0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family: \"Times New Roman\",serif;'\u003eTotal cholesterol (mg/dL)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e193.7 (43.1)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e181.2 (43.3)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.25pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e189.7 (48.5)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e183.3 (42.3)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.25pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e174.2 (40.4)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:131.4pt;border-top:none;border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;padding: 0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family: \"Times New Roman\",serif;'\u003eLDL-C (mg/dL)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e117.5 (36.5)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e105.9 (36.6)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.25pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e112.0 (39.2)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e106.1 (38.1)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.25pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e100.7 (35.3)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:131.4pt;border-top:none;border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;padding: 0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family: \"Times New Roman\",serif;'\u003eHDL-C (mg/dL)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e45.1 (10.9)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e44.4 (13.5)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.25pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e42.9 (11.9)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e42.8 (11.9)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.25pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e45.2 (13.2)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:131.4pt;border:solid windowtext 1.0pt;border-top: none;padding:0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family: \"Times New Roman\",serif;'\u003eTriglycerides (mg/dL)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border-top:none;border-left:none;border-bottom: solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding: 0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e169.8 (108.0)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border-top:none;border-left:none;border-bottom: solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding: 0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e168.1 (108.5)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.25pt;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e203.1 (275.0)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border-top:none;border-left:none;border-bottom: solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding: 0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e186.3 (114.9)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.25pt;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e141.5 (66.2)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:131.4pt;border:solid windowtext 1.0pt;border-top: none;padding:0in 5.4pt 0in 5.4pt;height:12.15pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family: \"Times New Roman\",serif;color:black;'\u003eStatin Use [n (%)]\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 67.2pt;border-color: currentcolor windowtext windowtext currentcolor;border-style: none solid solid none;border-width: medium 1pt 1pt medium;padding: 0in 5.4pt;height: 12.15pt;vertical-align: top;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family: \"Times New Roman\",serif;'\u003e63 (28.4%)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 67.2pt;border-color: currentcolor windowtext windowtext currentcolor;border-style: none solid solid none;border-width: medium 1pt 1pt medium;padding: 0in 5.4pt;height: 12.15pt;vertical-align: top;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family: \"Times New Roman\",serif;'\u003e46 (40.4%)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 67.25pt;border-color: currentcolor windowtext windowtext currentcolor;border-style: none solid solid none;border-width: medium 1pt 1pt medium;padding: 0in 5.4pt;height: 12.15pt;vertical-align: top;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family: \"Times New Roman\",serif;'\u003e91 (34.7%)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 67.2pt;border-color: currentcolor windowtext windowtext currentcolor;border-style: none solid solid none;border-width: medium 1pt 1pt medium;padding: 0in 5.4pt;height: 12.15pt;vertical-align: top;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family: \"Times New Roman\",serif;'\u003e113 (40.8%)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 67.25pt;border-color: currentcolor windowtext windowtext currentcolor;border-style: none solid solid none;border-width: medium 1pt 1pt medium;padding: 0in 5.4pt;height: 12.15pt;vertical-align: top;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family: \"Times New Roman\",serif;'\u003e84 (42.4%)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:131.4pt;border-top:none;border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;padding: 0in 5.4pt 0in 5.4pt;height:2.5pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family: \"Times New Roman\",serif;color:black;'\u003eTime from biopsy to study entry (days)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 67.2pt;border-color: currentcolor windowtext currentcolor currentcolor;border-style: none solid none none;border-width: medium 1pt medium medium;border-image: none 100% / 1 / 0 stretch;padding: 0in 5.4pt;height: 2.5pt;vertical-align: top;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family: \"Times New Roman\",serif;'\u003e55.16(24.32)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 67.2pt;border-color: currentcolor windowtext currentcolor currentcolor;border-style: none solid none none;border-width: medium 1pt medium medium;border-image: none 100% / 1 / 0 stretch;padding: 0in 5.4pt;height: 2.5pt;vertical-align: top;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family: \"Times New Roman\",serif;'\u003e60.44(26.93)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 67.25pt;border-color: currentcolor windowtext currentcolor currentcolor;border-style: none solid none none;border-width: medium 1pt medium medium;border-image: none 100% / 1 / 0 stretch;padding: 0in 5.4pt;height: 2.5pt;vertical-align: top;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family: \"Times New Roman\",serif;'\u003e53.60(25.24)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 67.2pt;border-color: currentcolor windowtext currentcolor currentcolor;border-style: none solid none none;border-width: medium 1pt medium medium;border-image: none 100% / 1 / 0 stretch;padding: 0in 5.4pt;height: 2.5pt;vertical-align: top;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family: \"Times New Roman\",serif;'\u003e53.18(24.15)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 67.25pt;border-color: currentcolor windowtext currentcolor currentcolor;border-style: none solid none none;border-width: medium 1pt medium medium;border-image: none 100% / 1 / 0 stretch;padding: 0in 5.4pt;height: 2.5pt;vertical-align: top;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family: \"Times New Roman\",serif;'\u003e79.31(39.22)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:131.4pt;border:solid windowtext 1.0pt;border-bottom: none;padding:0in 5.4pt 0in 5.4pt;height:2.5pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family: \"Times New Roman\",serif;'\u003eNAFL [n (%)]\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:2.5pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e195 (87.8%)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:2.5pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e23 (20.2%)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.25pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:2.5pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e0 (0.0%)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:2.5pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e0 (0.0%)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.25pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:2.5pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e7 (3.5%)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:131.4pt;border-top:none;border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;padding: 0in 5.4pt 0in 5.4pt;height:3.0pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family: \"Times New Roman\",serif;'\u003eNASH [n (%)]\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:3.0pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e27 (12.2%)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:3.0pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e91 (79.8%)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.25pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:3.0pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e262 (100%)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:3.0pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e277 (100%)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.25pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:3.0pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e178 (89.9%)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:131.4pt;border-top:none;border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;padding: 0in 5.4pt 0in 5.4pt;height:3.0pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family: \"Times New Roman\",serif;'\u003eSteatosis grade\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:3.0pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e1.3 (0.5)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:3.0pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e1.2 (0.4)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.25pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:3.0pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e2.0 (0.8)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:3.0pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e1.8 (0.9)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.25pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:3.0pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e1.3 (0.9)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:131.4pt;border-top:none;border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;padding: 0in 5.4pt 0in 5.4pt;height:3.0pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family: \"Times New Roman\",serif;'\u003eBallooning grade\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:3.0pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e0.1 (0.3)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:3.0pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e0.3 (0.5)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.25pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:3.0pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e1.2 (0.7)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:3.0pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e1.5 (0.7)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.25pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:3.0pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e1.5 (0.7)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:131.4pt;border-top:none;border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;padding: 0in 5.4pt 0in 5.4pt;height:3.0pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family: \"Times New Roman\",serif;'\u003eLobular Inflammation\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:3.0pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e1.0 (0.3)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:3.0pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e1.1 (0.3)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.25pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:3.0pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e1.7 (0.7)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:3.0pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e1.8 (0.7)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.25pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:3.0pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e1.5 (0.7)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:131.4pt;border-top:none;border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;padding: 0in 5.4pt 0in 5.4pt;height:3.0pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family: \"Times New Roman\",serif;'\u003ePortal inflammation\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:3.0pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e0.8 (0.6)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:3.0pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e0.9 (0.5)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.25pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:3.0pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e1.2 (0.5)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:3.0pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e1.4 (0.5)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.25pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:3.0pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e1.7 (0.5)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:131.4pt;border:solid windowtext 1.0pt;border-top: none;padding:0in 5.4pt 0in 5.4pt;height:3.0pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family: \"Times New Roman\",serif;'\u003eNAS\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border-top:none;border-left:none;border-bottom: solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding: 0in 5.4pt 0in 5.4pt;height:3.0pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e2.5 (0.6)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border-top:none;border-left:none;border-bottom: solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding: 0in 5.4pt 0in 5.4pt;height:3.0pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e2.5 (0.6)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.25pt;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:3.0pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e4.8 (1.5)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.2pt;border-top:none;border-left:none;border-bottom: solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding: 0in 5.4pt 0in 5.4pt;height:3.0pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e5.2 (1.6)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:67.25pt;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:3.0pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;color:black;'\u003e4.2 (1.6)\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cem\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;'\u003eAll statistics presented are means (standard deviations), unless otherwise specified.\u003c/span\u003e\u003c/em\u003e\u003c/p\u003e\n\u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cem\u003e\u003cspan style='font-size:13px;line-height:107%;font-family:\"Times New Roman\",serif;'\u003e*Time between the liver biopsy and study enrollment for 109 (10%) of the cohort was between 92-183 days.\u003c/span\u003e\u003c/em\u003e\u003c/p\u003e\n\u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style=\"font-size:13px;line-height:107%;\"\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n\u003ch2 style='margin-top:2.0pt;margin-right:0in;margin-bottom:6.0pt;margin-left:0in;line-height:107%;font-size:16px;font-family:\"Times New Roman\",serif;color:#2F5496;'\u003eTable 2: \u0026nbsp;Sensitivity and Specificity of individual panels for their intended use\u003c/h2\u003e\n\u003ctable style=\"width: 4.5e+2pt;border: none;border-collapse:collapse;\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"2\" style=\"width: 93.9pt;border-color: windowtext windowtext black;border-style: solid;border-width: 1pt;border-image: none 100% / 1 / 0 stretch;padding: 0in 5.4pt;height: 12.05pt;vertical-align: bottom;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width:63.1pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid black 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:center;'\u003e\u003cstrong\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003eSensitivity(%)\u003c/span\u003e\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width:63.0pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:solid black 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:center;'\u003e\u003cstrong\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003eSpecificity (%)\u003c/span\u003e\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:.75in;border-top:solid windowtext 1.0pt;border-left: none;border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:center;'\u003e\u003cstrong\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003eYouden\u003c/span\u003e\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:99.0pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:center;'\u003e\u003cstrong\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003eAUROC\u003c/span\u003e\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:76.35pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:center;'\u003e\u003cstrong\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003eSignificance\u003c/span\u003e\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:.75in;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:center;'\u003e\u003cstrong\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003eindex\u003c/span\u003e\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:99.0pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:center;'\u003e\u003cstrong\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e(95% CI)\u003c/span\u003e\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:76.35pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:center;'\u003e\u003cstrong\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e(vs ALT or FIB4)\u003c/span\u003e\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:93.9pt;border-top:none;border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cstrong\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003eNASH Diagnosis\u003c/span\u003e\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:63.1pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:63.0pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:.75in;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:99.0pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:76.35pt;border-top:solid windowtext 1.0pt;border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:93.9pt;border-top:none;border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;background:#F2F2F2;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:63.1pt;border:none;border-right:solid windowtext 1.0pt;background:#F2F2F2;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:63.0pt;border:none;border-right:solid windowtext 1.0pt;background:#F2F2F2;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:.75in;border:none;border-right:solid windowtext 1.0pt;background:#F2F2F2;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:99.0pt;border:none;border-right:solid windowtext 1.0pt;background:#F2F2F2;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:76.35pt;border:none;border-right:solid windowtext 1.0pt;background:#F2F2F2;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:93.9pt;border-top:none;border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003eALT\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:63.1pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e63.2\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:63.0pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e64.8\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:.75in;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e0.28\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:99.0pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e0.678[0.639,0.717]\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:76.35pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:93.9pt;border-top:none;border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003eNIS4\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:63.1pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e77.7\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:63.0pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e76.2\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:.75in;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e0.539\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:99.0pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e0.832[0.801,0.864]\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:76.35pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026lt;0.001\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:93.9pt;border:solid windowtext 1.0pt;border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.45pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003eOWL\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:63.1pt;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.45pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e77.3\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:63.0pt;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.45pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e66.8\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width:153.0pt;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.45pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:center;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003eCategorical Data\u003c/span\u003e\u003c/p\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:center;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003eAUROC can\u0026rsquo;t be computed\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:76.35pt;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.45pt;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:93.9pt;border-top:none;border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cstrong\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003eNAS \u0026ge; 4\u003c/span\u003e\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:63.1pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:63.0pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:.75in;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:99.0pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:76.35pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:93.9pt;border-top:none;border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;background:#F2F2F2;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:63.1pt;border:none;border-right:solid windowtext 1.0pt;background:#F2F2F2;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:63.0pt;border:none;border-right:solid windowtext 1.0pt;background:#F2F2F2;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:.75in;border:none;border-right:solid windowtext 1.0pt;background:#F2F2F2;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:99.0pt;border:none;border-right:solid windowtext 1.0pt;background:#F2F2F2;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:76.35pt;border:none;border-right:solid windowtext 1.0pt;background:#F2F2F2;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:93.9pt;border-top:none;border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003eALT\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:63.1pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e71.1\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:63.0pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e64.1\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:.75in;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e0.352\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:99.0pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e0.726[0.694,0.759]\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 76.35pt;border-color: currentcolor windowtext currentcolor currentcolor;border-style: none solid none none;border-width: medium 1pt medium medium;border-image: none 100% / 1 / 0 stretch;padding: 0in 5.4pt;height: 12.05pt;vertical-align: bottom;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:93.9pt;border-top:none;border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003eNIS4\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:63.1pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e78.1\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:63.0pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e73.6\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:.75in;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e0.517\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:99.0pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e0.815[0.786,0.844]\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:76.35pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026lt;0.001\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:93.9pt;border:solid windowtext 1.0pt;border-top:none;padding:0in 5.4pt 0in 5.4pt;height:11.7pt;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd style=\"width:63.1pt;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:11.7pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:63.0pt;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:11.7pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width:153.0pt;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:11.7pt;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd style=\"width:76.35pt;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:11.7pt;\"\u003e\u003cbr\u003e\u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:93.9pt;border-top:none;border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cstrong\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003eAt risk NASH \u0026nbsp;\u003c/span\u003e\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:63.1pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:63.0pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:.75in;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:99.0pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:76.35pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:93.9pt;border-top:none;border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;background:#F2F2F2;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:63.1pt;border:none;border-right:solid windowtext 1.0pt;background:#F2F2F2;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:63.0pt;border:none;border-right:solid windowtext 1.0pt;background:#F2F2F2;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:.75in;border:none;border-right:solid windowtext 1.0pt;background:#F2F2F2;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:99.0pt;border:none;border-right:solid windowtext 1.0pt;background:#F2F2F2;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:76.35pt;border:none;border-right:solid windowtext 1.0pt;background:#F2F2F2;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:93.9pt;border-top:none;border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003eALT\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:63.1pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e71.1\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:63.0pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e64.1\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:.75in;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e0.352\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:99.0pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e0.726[0.694. 0.759]\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:76.35pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:93.9pt;border-top:none;border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003eFIB4\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:63.1pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e76.4\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:63.0pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e58.4\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:.75in;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e0.349\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:99.0pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e0.704[0.671, 0.737]\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:76.35pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:93.9pt;border:solid windowtext 1.0pt;border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.45pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003eNIS4\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:63.1pt;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.45pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e78.1\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:63.0pt;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.45pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e73.6\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:.75in;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.45pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e0.517\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:99.0pt;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.45pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e0.815[0.786.0.844]\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:76.35pt;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.45pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026lt;0.001\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:93.9pt;border-top:none;border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cstrong\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003eFibrosis stage \u0026ge; 2\u003c/span\u003e\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:63.1pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:63.0pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:.75in;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:99.0pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:76.35pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:93.9pt;border-top:none;border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;background:#F2F2F2;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:63.1pt;border:none;border-right:solid windowtext 1.0pt;background:#F2F2F2;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:63.0pt;border:none;border-right:solid windowtext 1.0pt;background:#F2F2F2;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:.75in;border:none;border-right:solid windowtext 1.0pt;background:#F2F2F2;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:99.0pt;border:none;border-right:solid windowtext 1.0pt;background:#F2F2F2;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:76.35pt;border:none;border-right:solid windowtext 1.0pt;background:#F2F2F2;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:93.9pt;border-top:none;border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003eFIB4\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:63.1pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e65.6\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:63.0pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e80.6\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:.75in;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e0.462\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:99.0pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e0.798[0.768,0.828]\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:76.35pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:93.9pt;border-top:none;border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003eELF test\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:63.1pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e71.8\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:63.0pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e81.5\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:.75in;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e0.533\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:99.0pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e0.828[0.08,0.857]\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:76.35pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e0.013\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:93.9pt;border-top:none;border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003eNIS4\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:63.1pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e82.3\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:63.0pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e79.9\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:.75in;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e0.622\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:99.0pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e0.874[0.848,0.899]\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:76.35pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026lt;0.001\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:93.9pt;border-top:none;border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003ePROC3\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:63.1pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e69.8\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:63.0pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e81\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:.75in;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e0.507\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:99.0pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e0.809[0.779,0.839]\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:76.35pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e0.279\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:93.9pt;border:solid windowtext 1.0pt;border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.45pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003eFibrometer VCTE\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:63.1pt;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.45pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e66.7\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:63.0pt;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.45pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e86.4\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:.75in;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.45pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e0.53\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:99.0pt;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.45pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e0.841[0.796,0.886]\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:76.35pt;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.45pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026lt;0.001\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:93.9pt;border-top:none;border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cstrong\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003eFibrosis stage \u0026ge; 3\u003c/span\u003e\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:63.1pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:63.0pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:.75in;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:99.0pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:76.35pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:93.9pt;border-top:none;border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;background:#F2F2F2;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:63.1pt;border:none;border-right:solid windowtext 1.0pt;background:#F2F2F2;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:63.0pt;border:none;border-right:solid windowtext 1.0pt;background:#F2F2F2;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:.75in;border:none;border-right:solid windowtext 1.0pt;background:#F2F2F2;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:99.0pt;border:none;border-right:solid windowtext 1.0pt;background:#F2F2F2;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:76.35pt;border:none;border-right:solid windowtext 1.0pt;background:#F2F2F2;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:93.9pt;border-top:none;border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003eFIB4\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:63.1pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e70.3\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:63.0pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e72.4\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:.75in;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e0.427\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:99.0pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e0.789[0.758,0.819]\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:76.35pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:93.9pt;border-top:none;border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003eELF\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:63.1pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e80.8\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:63.0pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e70.2\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:.75in;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e0.509\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:99.0pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e0.835[0.807,0.863]\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:76.35pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026lt;0.001\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:93.9pt;border-top:none;border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003eNIS4\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:63.1pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e72.9\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:63.0pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e74.8\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:.75in;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e0.476\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:99.0pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e0.788[0.757,0.820]\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:76.35pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e0.615\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:93.9pt;border-top:none;border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003ePROC3\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:63.1pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e71.4\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:63.0pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e71.4\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:.75in;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e0.428\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:99.0pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e0.764[0.732,0.795]\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:76.35pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e0.947\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:93.9pt;border:solid windowtext 1.0pt;border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.45pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003eFibrometer VCTE\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:63.1pt;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.45pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e76.2\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:63.0pt;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.45pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e81.3\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:.75in;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.45pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e0.575\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:99.0pt;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.45pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e0.858[0.814,0.902]\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:76.35pt;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.45pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026lt;0.001\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:93.9pt;border-top:none;border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cstrong\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003eFibrosis stage 4\u003c/span\u003e\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:63.1pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:63.0pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:.75in;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:99.0pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:76.35pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:93.9pt;border-top:none;border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;background:#F2F2F2;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:63.1pt;border:none;border-right:solid windowtext 1.0pt;background:#F2F2F2;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:63.0pt;border:none;border-right:solid windowtext 1.0pt;background:#F2F2F2;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:.75in;border:none;border-right:solid windowtext 1.0pt;background:#F2F2F2;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:99.0pt;border:none;border-right:solid windowtext 1.0pt;background:#F2F2F2;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:76.35pt;border:none;border-right:solid windowtext 1.0pt;background:#F2F2F2;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:93.9pt;border-top:none;border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003eFIB4\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:63.1pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e84.7\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:63.0pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e62.9\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:.75in;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e0.476\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:99.0pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e0.810[0.770,0.850]\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:76.35pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:93.9pt;border-top:none;border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003eELF\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:63.1pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e82.1\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:63.0pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e73.3\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:.75in;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e0.555\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:99.0pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e0.855[0.818,0.892]\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:76.35pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e\u0026lt;0.001\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:93.9pt;border-top:none;border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003eNIS4\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:63.1pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e78.1\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:63.0pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e61.4\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:.75in;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e0.395\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:99.0pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e0.725[0.681,0.760]\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:76.35pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e1\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:93.9pt;border-top:none;border-left:solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003ePROC3\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:63.1pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e66.2\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:63.0pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e68.5\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:.75in;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e0.346\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:99.0pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e0.728[0.685,0.770]\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:76.35pt;border:none;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.05pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e1\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:93.9pt;border:solid windowtext 1.0pt;border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.45pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003eFibrometer VCTE\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:63.1pt;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.45pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e94.2\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:63.0pt;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.45pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e70.4\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:.75in;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.45pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e0.646\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:99.0pt;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.45pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e0.897[0.843,0.951]\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:76.35pt;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:12.45pt;\"\u003e\n \u003cp style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:0in;line-height:normal;font-size:15px;font-family:\"Calibri\",sans-serif;text-align:right;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;color:black;'\u003e0.002\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;'\u003e*for NASH diagnosis, NAS \u0026ge; 4, significance is computed from comparison to AUROC for ALT\u003c/span\u003e\u003c/p\u003e\n\u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;'\u003e**for \u0026ldquo;at risk\u0026rdquo; NASH, the significance values are against AUROCS for both ALT and for FIB4\u003c/span\u003e\u003c/p\u003e\n\u003cp style='margin-top:0in;margin-right:0in;margin-bottom:8.0pt;margin-left:0in;line-height:107%;font-size:15px;font-family:\"Calibri\",sans-serif;'\u003e\u003cspan style='font-family:\"Times New Roman\",serif;'\u003e*** for fibrosis cutoffs, significance is computed from comparison to AUROC for FIB4\u003c/span\u003e\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eConflicts of Interest:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eDr. Arun Sanyal: Dr. Sanyal has stock options in Genfit, Akarna, Tiziana, Indalo, Durect Inversago and Galmed. He has served as a consultant to Astra Zeneca, Nitto Denko, Conatus, Nimbus, Salix, Tobira, Takeda, Jannsen, Gilead, Terns, Birdrock, Merck, Valeant, Boehringer-Ingelheim, Bristol Myers Squibb, Lilly, Hemoshear, Zafgen, Novartis, Novo Nordisk, Pfizer, Exhalenz and Genfit. He has been an unpaid consultant to Intercept, Echosens, Immuron, Galectin, Fractyl, Target-Pharma, Syntlogic, Affimune, Chemomab, Zydus, Nordic Bioscience, Albireo, Prosciento, Surrozen. His institution has received grant support from Gilead, Salix, Tobira, Bristol Myers, Shire, Intercept, Merck, Astra Zeneca, Malinckrodt, Cumberland and Novartis. He receives royalties from Elsevier and UptoDate. \u0026nbsp;He recused himself from the analysis and interpretation of NIS4.\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eSudha Shankar: \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; Dr. Shankar is an employee of Astra Zeneca.\u003c/p\u003e\n\u003cp\u003eKatherine Yates: \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; Ms. Yates has no conflicts to report.\u003c/p\u003e\n\u003cp\u003eJames Bolognese: \u0026nbsp; \u0026nbsp; \u0026nbsp; Mr. Bolognese is a paid consultant for Cytel, Inc.\u003c/p\u003e\n\u003cp\u003eErica Daly: \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Dr. Daly is an employee of Cytel, Inc.\u003c/p\u003e\n\u003cp\u003eClayton Dehn: \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; Mr. Dehn is a volunteer consultant for NIMBLE (P-value, LLC)\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eBrent Neuschwander-Tetri: \u0026nbsp; \u0026nbsp;Consultant or advisor for Akero, Alimentiv, Allergan, Allysta, Alnylam, Amgen, Arrowhead, Axcella, Boehringer Ingelheim, BMS, Coherus, Cymabay, Durect, Enanta, Fortress, Genfit, Gilead, Glympse, GSK, Hepeon, High Tide, HistoIndex, Innovo, Intercept, Ionis, LG Chem, Lipocine, Madrigal, Medimmune, Merck, Mirum, NGM, NovoNordisk, Novus Therapeutics, pH-Pharma, Sagimet, Target RWE, Theratechnologies, 89Bio; Institutional research grants: Allergan, BMS, Celgene, Cirius, Enanta, Genfit, Gilead, HighTide, Intercept, Madrigal, NGM; Stock options in HepGene.\u003c/p\u003e\n\u003cp\u003eKris Kowdley: \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Dr. Kowdley has received Grant/research/clinical trial support from Corcept, CymaBay, Genfit, Gilead, GSK, Hanmi, Intercept, Madrigal, Mirum, Novo Nordisk, NGM, Pfizer, Pliant, Terns, Viking, 89bio. He has served as Consultant or on advisory boards from CymaBay, Enanta, Genfit, Gilead, HighTide, Inipharm, Intercept, Madrigal, Mirum, NGM, Pfizer, 89bio. He sevres on the Speaker\u0026rsquo;s bureau for AbbVie, Gilead, Intercept and has Stock options from Inipharm.\u003c/p\u003e\n\u003cp\u003eRaj Vuppalanchi: \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Dr. Vuppalanchi receives institutional research grant support from Zydus Therapeutics, Galectin Therapeutics, Gilead Sciences, Novo Nordisk, Eli Lilly, and also discloses consulting for LabCorp, GSK, Medpace, GW Pharma, Daichi Sankyo, and Echosens.\u003c/p\u003e\n\u003cp\u003eCynthia Behling: \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; Dr. Behling has provided consulting or participated in seminars/preceptorships for Alimentev, Pfizer and Novo Nordisk. Dr. Cynthia Behling\u0026rsquo;s institution (Pacific Rim Pathology Laboratory/Analytic Pathology Medical Group) currently receives support for biopsy related work through nonexclusive laboratory services and/or consulting agreements with: Akero Therapeutics Inc, Covance, E study site, Genesis Imaging Service, ICON, Medical Research Group, Inc., Southern California Research Center.\u003c/p\u003e\n\u003cp\u003eJames Tonascia: \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Dr. Tonascia has no conflicts to report.\u003c/p\u003e\n\u003cp\u003eAnthony Samir: \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Dr. Samir has provided consulting for General Electric and Gerson Lehman Group, is a member of the Advisory or Scientific Board for General Electric, Rhino Healthtech, Ochre Bio, and Foundation for the National Institutes of Health; has research support from Canon, Echosens, General Electric, Philips, Siemens, Supersonic Imagine/Hologic and has research funding from Analogic Corporation, Department of Defense, Fujifilm Healthcare, Foundation for the National Institutes of Health, and General Electric; and has equity in Avira Inc., Autonomus LLC, Evidence Based Psychology LLC, Klea LLC, Katharos Labs LLC, Quantix Bio LLC, and Sonoluminous LLC.\u003c/p\u003e\n\u003cp\u003eClaude Sirlin: \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Dr. Sirlin reports research grants from ACR, Bayer, Foundation of NIH, GE, Gilead, Pfizer, Philips, Siemens; lab service agreements with Enanta, Gilead, ICON, Intercept, Nusirt, Shire, Synageva, Takeda; institutional consulting for BMS, Exact Sciences, IBM-Watson, Pfizer; Personal consulting for Blade, Boehringer, Epigenomics; and Guerbet; receipt of royalties and/or honoraria from Medscape and Wolters Kluwer; ownership of stock options in Livivos; unpaid advisory board position in Quantix Bio. Dr. Sirlin has been approved by his university to serve as Chief Medical Officer for Livivos (to be an unsalaried position with stock options).\u003c/p\u003e\n\u003cp\u003eSarah Sherlock: \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Dr. Sherlock is an employee of Pfizer, Inc. and has shares/stock options.\u003c/p\u003e\n\u003cp\u003eKathryn Fowler \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Dr. Fowler Dr. Fowler reports institutional research support from Bayer, Foundation of NIH, GE, Gilead, Pfizer, Philips, Siemens; lab service agreements with Enanta, Gilead, ICON, Intercept, Nusirt, Shire, Synageva, Takeda; personal consulting-Bayer, GE, Epigenomics. Unpaid advisory board Quantix Bio. \u0026nbsp;\u003c/p\u003e\n\u003cp\u003eHelen Heymann \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Ms. Heymann has no conflicts to report.\u003c/p\u003e\n\u003cp\u003eTania Kamphaus: \u0026nbsp; \u0026nbsp; \u0026nbsp; Dr. Kamphaus has no conflicts to report.\u003c/p\u003e\n\u003cp\u003eDr. Loomba: \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; Dr. Loomba serves as a consultant or advisory board member for 89bio, Alnylam, Arrowhead Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Bristol-Myer Squibb, Cirius, CohBar, DiCerna, Galmed, Gilead, Glympse bio, Intercept, Ionis, Metacrine, NGM Biopharmaceuticals, Novo Nordisk, Pfizer, Sagimet and Viking Therapeutics. In addition, his institution has received grant support from Allergan, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, Galmed Pharmaceuticals, Genfit, Gilead, Intercept, Inventiva, Janssen, Madrigal Pharmaceuticals, NGM Biopharmaceuticals, Novartis, Pfizer, pH Pharma, and Siemens. \u0026nbsp;He is also co-founder of Liponexus, Inc.\u003c/p\u003e\n\u003cp\u003eRoberto Calle: \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;Dr. Calle is an employee of Regeneron Pharmaceuticals, Inc. and owns stock in both Regeneron and Pfizer.\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eSource of funding\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe authors thank the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) investigators and the Ancillary Studies Committee for providing clinical samples and relevant data from the Nonalcoholic Fatty Liver Disease (NAFLD) Database, Nonalcoholic Fatty Liver Disease (NAFLD) Adult Database 2, PIVENS trial, and FLINT trial.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eThis work was partially funded by the NIDDK (grants U01DK061731, U01DK061730, U24DK061730) and the National Center for Advancing Translational Sciences (NCATS) grant UL1TR002649.\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eThe PIVENS trial was conducted by the NASH CRN and supported in part by Takeda Pharmaceuticals North America through a Cooperative Research and Development Agreement with the NIDDK. The vitamin E and matching placebo for the PIVENS trial were provided by Pharmavite through a Clinical Trial Agreement with the NIH. The FLINT trial was conducted by the NASH CRN and supported in part by a Collaborative Research and Development Agreement (CRADA) between NIDDK and Intercept Pharmaceuticals.\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eFNIH-NIMBLE project-\u0026nbsp;Foundation for the National Institutes of Health (FNIH) -Biomarkers Consortium, Non-Invasive Biomarkers for Metabolic Liver Disease (NIMBLE) Project\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eThe FNIH creates and manages alliances with public and private institutions in support of the mission of the NIH, the world\u0026rsquo;s premier medical research agency. The FNIH works with its partners to accelerate biomedical research and strategies for addressing diseases and health concerns in the United States and across the globe. The FNIH organizes and administers research projects; supports education and training of new researchers; organizes educational events and symposia; and administers a series of funds supporting a wide range of health issues. Established by Congress in 1990, the FNIH is a not-for-profit 501(c)(3) charitable organization.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eThe NIMBLE Project is a comprehensive multi-year pre-competitive, public-private partnership conducted under the auspices of the FNIH- Biomarkers Consortium. The Biomarkers Consortium embraces government, industry, patient advocacy groups, and not-for-profit organizations each of which has a stake in the identification, development, and the seeking of regulatory approval for biomarkers.\u0026nbsp;The NIMBLE project is sponsored by the FNIH and is a public\u0026ndash;private partnership supported by multiple entities including AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Echosens, GE Healthcare, Genentech, Gilead Sciences, Intercept Pharmaceuticals, Novo Nordisk, Pfizer Inc, Regeneron Pharmaceuticals and Takeda Development Center Americas. We acknowledge support from the Global Liver Institute, USA, and the US FDA.\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eThe FNIH NIMBLE study was conducted by the NASH CRN and FNIH Investigators and supported by NIDDK. The biospecimens from the NASH CRN reported here were supplied by the NIDDK Central Repository. This manuscript was not prepared in collaboration with the NIDDK Central Repository and does not necessarily reflect the opinions or views of the NIDDK Central Repository.\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eKey collaborators who provide in-kind support to NIMBLE include AMRA Medical, Canon Medical Systems USA, Echosens, GENFIT, GE Healthcare, Nordic Bioscience, OWL Metabolomics, Philips Ultrasound, P-Value, Hologic SuperSonic Imagine, Siemens Healthineers and Siemens Medical Solutions USA. \u0026nbsp;The laboratories that performed the chemical analyses and reported raw data to the NIMBLE data coordinating center were as follows:\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eNIS4 (Genfit and Labcorp), Lille, France\u003c/p\u003e\n\u003cp\u003eELF test: \u0026nbsp;Siemens Healthineers, California, USA\u003c/p\u003e\n\u003cp\u003ePROC3: \u0026nbsp;Nordic Biosciences, Copenhagen, Denmark\u003c/p\u003e\n\u003cp\u003eOwliver: \u0026nbsp;One Way Lipidomics (OWL), Bilbao, Spain\u003c/p\u003e\n\u003cp\u003eFibrometer VCTE: \u0026nbsp;Echosens, Paris, France\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eData Availability Statement:\u003c/strong\u003e\u0026nbsp; Included in supplemental materials\u003c/p\u003e"},{"header":"Abbreviations","content":"\u003cp\u003eNonalcoholic fatty liver disease (NAFLD), Nonalcoholic steatohepatitis (NASH), NAFLD activity score (NAS), Body Mass Index (BMI), Type 2 Diabetes Mellitus (T2DM), \u003c/p\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":true,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"nature-portfolio","isNatureJournal":true,"hasQc":false,"allowDirectSubmit":false,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"","title":"Nature Portfolio","twitterHandle":"","acdcEnabled":false,"dfaEnabled":false,"editorialSystem":"ejp","reportingPortfolio":"","inReviewEnabled":true,"inReviewRevisionsEnabled":false},"keywords":"Nonalcoholic fatty liver disease (NAFLD), Nonalcoholic steatohepatitis (NASH), NAFLD activity score (NAS), Fibrosis stage, cirrhosis, steatohepatitis, fibrosis, biomarkers, diagnostic panel, context of use, validation","lastPublishedDoi":"10.21203/rs.3.rs-2492725/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-2492725/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003ch2\u003eBackground\u003c/h2\u003e \u003cp\u003eThere are no approved noninvasive tests (NIT) for the diagnosis of nonalcoholic steatohepatitis (NASH) and its histological phenotypes.\u003c/p\u003e\u003ch2\u003eMethods\u003c/h2\u003e \u003cp\u003eThe FNIH-NIMBLE consortium tested 5 serum-based NIT panels for the following intended uses: NIS4: At-risk NASH, a composite of NASH with NAFLD activity score (NAS)\u0026thinsp;\u0026ge;\u0026thinsp;4 and fibrosis stage\u0026thinsp;\u0026ge;\u0026thinsp;2, OWLiver: NASH and NAS\u0026thinsp;\u0026ge;\u0026thinsp;4, enhanced liver fibrosis (ELF), PROC3 and Fibrometer VCTE: fibrosis stages\u0026thinsp;\u0026ge;\u0026thinsp;2, \u0026ge; 3 or 4. Aliquots from a single blood sample obtained within 90 days of histological confirmation of NAFLD were tested. The prespecified performance metric tested for was a diagnostic AUROC greater than 0.7 and superiority to ALT for diagnosis of NASH or NAS\u0026thinsp;\u0026ge;\u0026thinsp;4 and to FIB-4 for fibrosis.\u003c/p\u003e\u003ch2\u003eResults\u003c/h2\u003e \u003cp\u003eA total of 1073 adults including NASH (n\u0026thinsp;=\u0026thinsp;848), at-risk NASH (n\u0026thinsp;=\u0026thinsp;539) and fibrosis stages 0\u0026ndash;4 (n\u0026thinsp;=\u0026thinsp;222, 114, 262, 277 and 198 respectively) were studied. The AUROC of NIS4 for at-risk NASH was 0.81 and superior to ALT and FIB4 (p\u0026thinsp;\u0026lt;\u0026thinsp;0.001 for both). OWliver diagnosed NASH with sensitivity and specificity of 77.3% and 66.8% respectively. The AUROCs (95% CI) of ELF, PROC3 and Fibrometer VCTE respectively for fibrosis were as follows: \u0026ge; stage 2 fibrosis [0.82 (0.8\u0026ndash;0.85), 0.8 (0.77\u0026ndash;0.83), and 0.84 (0.79\u0026ndash;0.88)], \u0026ge; stage 3 [0.83 (0.8\u0026ndash;0.86), 0.76 (0.73\u0026ndash;0.79), 0.85 (0.81\u0026ndash;0.9), stage 4 [0.85 (0.81\u0026ndash;0.89), 0.81 (0.77\u0026ndash;0.85), 0.89 (0.84\u0026ndash;0.95)]. ELF and Fibrometer VCTE were significantly superior to FIB-4 for all fibrosis endpoints (p\u0026thinsp;\u0026lt;\u0026thinsp;0.01 for all).\u003c/p\u003e\u003ch2\u003eConclusions\u003c/h2\u003e \u003cp\u003eThese data support the further development of NIS4, ELF and Fibrometer VCTE for their intended uses.\u003c/p\u003e","manuscriptTitle":"The Nimble Stage 1 Study Validates Diagnostic Circulating Biomarkers for Nonalcoholic Steatohepatitis","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2023-01-19 21:45:04","doi":"10.21203/rs.3.rs-2492725/v1","editorialEvents":[],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"nature-medicine","isNatureJournal":true,"hasQc":false,"allowDirectSubmit":false,"externalIdentity":"nm","sideBox":"Learn more about [Nature Medicine](http://www.nature.com/nm/)","snPcode":"","submissionUrl":"","title":"Nature Medicine","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"ejp","reportingPortfolio":"Nature Research","inReviewEnabled":true,"inReviewRevisionsEnabled":false}}],"origin":"","ownerIdentity":"1cc73f17-2f05-4572-a00d-ce60c9ae141b","owner":[],"postedDate":"January 19th, 2023","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"published-in-journal","subjectAreas":[{"id":18556013,"name":"Health sciences/Biomarkers/Diagnostic markers"},{"id":18556014,"name":"Health sciences/Biomarkers"}],"tags":[],"updatedAt":"2023-09-29T14:51:44+00:00","versionOfRecord":{"articleIdentity":"rs-2492725","link":"https://doi.org/10.1038/s41591-023-02539-6","journal":{"identity":"nature-medicine","isVorOnly":false,"title":"Nature Medicine"},"publishedOn":"2023-09-07 04:00:00","publishedOnDateReadable":"September 7th, 2023"},"versionCreatedAt":"2023-01-19 21:45:04","video":"","vorDoi":"10.1038/s41591-023-02539-6","vorDoiUrl":"https://doi.org/10.1038/s41591-023-02539-6","workflowStages":[]},"version":"v1","identity":"rs-2492725","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-2492725","identity":"rs-2492725","version":["v1"]},"buildId":"7rjqhiLT3MXkJMwkYKINL","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}